

Essential Medicines And Patents: Recent Trends In The Latest Editions Of The World Health Organization

Appendix A:

Methodology

The goal of this paper was to analyze changes and trends across three of the most editions of the WHO's Essential Medicines List. Specific objectives of this project were three-fold: 1) analyze the percentage of patented drugs on the EML for the 19th (2015), 20th (2017), and 21st (2019) editions; 2) determine, to the extent possible, the patent status for each drug on the EML with regard to a sample of 150 lower income countries of medicines on the 21st EML as well as the existence of any voluntary licensing program, and 3) analyze trends and changes concerning the use and submission of new drugs for consideration of placement on the EML across the three most recent editions of the EML, the 19th, 20th, and 21st.

Objective 1

We largely employed the methodology used by Beall and Attaran (2016) to determine which drugs were patented and where. For the sake of timeliness, we were able to abbreviate some steps using public resources that have become available since the time of that study.

The steps to determine whether a drug on the EML is "patented" according to the Beall-Attaran methodology can be summed up as follows:

- 1) First, check to determine if a drug was approved for sale in the US or Canada.
- 2) Second, check whether the drug was listed as patented in the Orange Book or on Health Canada's Patent Registry.

- 3) Third, check whether generics were available for the use indicated on the EML. If the drug was approved for sale in the US or Canada, listed as patented, and no generics were available, then it counted as patented. If it was listed as unpatented and/or generics were available, it was considered not subject to patent.
- 4) If the drug was not approved for sale in the US or Canada, or a biologic, Beall-Attaran performed further research using a commercial database to determine patent status. We were able to use the MedsPal Database for much of this research, and for about 10 drugs not listed on MedsPal, we used a commercial database, DrugPatentWatch, which focuses on providing specialized information regarding drug patents.
- 5) If the drug was patented, Beall and Attaran also used a commercial database to determine where patents existed, how many, and the date of first and last expiration. Here, we were able to rely on MedsPal and DrugPatentWatch.
- 6) Lastly, they verified results with pharmaceutical manufacturers, as there are known to be gaps in databases. As Beall and Attaran acknowledge, this step was a challenging and lengthy process. Instead, we used a newer public database, PatInformed, which contains information submitted by most pharmaceutical manufacturers to the World Intellectual Property Organization regarding the patent status of their drugs worldwide. One stated goal of PatInformed is to help medicine procurement agencies to determine if a drug is under patent. Presumably, innovative companies thus have an incentive to ensure that the information in PatInformed is complete. We considered PatInformed to play a similar role as making direct inquiries to pharmaceutical companies regarding patent status of medicines, and thus an acceptable substitute for Beall & Attaran's step of direct verification.

Objective 2

Using the MedsPal database, supplemented by DrugPatentWatch for nine drugs, we determined how many active patent listings, if any, exist in the relevant jurisdictions, as well as the first and last dates of expiration for said patents. Active filings are those listed as "filed," "filed but opposed," "granted," "granted but opposed," or "rejected but under appeal" with an expected expiration date of January 1, 2020, or later. The relevant jurisdictions are low and middle income countries as that term is typically defined by the United Nations. These were also the 150 lower income countries listed in MedsPal, so that was where data was available.

Afghanistan	Costa Rica	Kyrgyz Republic	Rwanda
Albania	Côte d'Ivoire	Lao PDR	Saint Kitts and Nevis
Algeria	Cuba	Lebanon	Saint Lucia
Angola	Djibouti	Lesotho	Saint Vincent and the Grenadines
Antigua and Barbuda	Dominica	Liberia	
Argentina	Dominican Republic	Libya	
Armenia	Ecuador	Madagascar	
Aruba	Egypt	Malawi	Samoa
Azerbaijan	El Salvador	Malaysia	Sao Tome and Principe
Bahamas	Equatorial Guinea	Maldives	Senegal
Bangladesh	Eritrea	Mali	Serbia
Barbados	Eswatini (formerly Swaziland)	Marshall Islands	Seychelles
Belarus	Ethiopia	Mauritania	Sierra Leone
Belize	Fiji	Mauritius	Solomon Islands
Benin	Gabon	Mexico	Somalia
Bhutan	Gambia	Micronesia	South Africa
Bolivia	Georgia	Moldova, Republic of	South Sudan
Bosnia and Herzegovina	Ghana	Mongolia	Sri Lanka
Botswana	Grenada	Montenegro	Sudan
Brazil	Guatemala	Morocco	Suriname
Burkina Faso	Guinea	Mozambique	Syrian Arab Republic
Burundi	Guinea-Bissau	Myanmar	Tajikistan
Cabo Verde	Guyana	Namibia	Tanzania, United Republic of
Cambodia	Haiti	Nauru	Thailand
Cameroon	Honduras	Nepal	Timor-Leste
Central African Republic	India	Nicaragua	Togo
Chad	Indonesia	Niger	Tonga
Chile	Iran (Islamic Republic of)	Nigeria	Trinidad and Tobago
China	Iraq	North Macedonia	Tunisia
Colombia	Jamaica	Pakistan	Turkey
Comoros	Jordan	Palau	Turkmenistan
Congo	Kazakhstan	Panama	Turks and Caicos Islands
Congo, the democratic Republic of the	Kenya	Papua New Guinea	Tuvalu
	Kiribati	Paraguay	Uganda
	Korea, DPR of	Peru	
	Kosovo	Philippines	
		Russian Federation	

Ukraine	Vanuatu	West Bank and	Yugoslavia/Serbia
United Arab	Venezuela	Gaza	and
Emirates	Viet Nam	Yemen	Montenegro
Uruguay	Virgin Islands		Zambia
Uzbekistan	(British)		Zimbabwe

All information on the relevant medicine was downloaded from the database then sorted. Irrelevant patents (i.e. – patents for other combinations, forms not covered on the EML, jurisdictions not within our scope) and inactive patents (expired, withdrawn, rejected, etc.) were removed first. If any duplicate patents existed within one jurisdiction, they were also removed.

Once a complete list of active patents, jurisdictions, and expected expiration dates was compiled, we determined the total number of jurisdictions with active filings, total number of active filings, first date of expiration, and last date of expiration for each medicine. Since all active filings were considered, the last date of expiration may be for a patent that is not yet granted. For those medicines researched using MedsPal, any relevant MPP licenses, bilateral licenses, and/or commitments to not enforce were noted next to the jurisdictions covered for that item. Any patents expiring in 2020 were also noted at this time.

Some MPP licenses, bilateral licenses, and commitments to not enforce cover multiple patents and medicines. For example, one commitment to not enforce covers lopinavir+ritonavir and ritonavir. Likewise, dolutegravir and dolutegravir+lamivudine+tenofovir are covered by the same MPP and bilateral licenses.

Objective 3

We reviewed additions to the EML to determine what each of the new additions were used for and separated them into general use categories such as cancer, contraceptives, hepatitis, HIV/AIDS, MDRs, and NCDs. Medicines that did not belong to a broader category – such as thyroid, diabetes, or postpartum hemorrhaging treatments – were classified as “other”, with a separate note concerning their use.

We also determined who submitted the medicines for consideration on the EML. Unfortunately, information provided on the WHO website is inconsistent between editions and incomplete overall. As of the time of this undertaking, no submission information for the 2019 EML is yet available, and not all new additions are represented in the applications proffered for 2017 and 2015 on the WHO website.

Using the available information on the WHO website concerning applications, we separated submissions into six categories: Academic/Practitioner, Manufacturer, NGO, WHO, Other, and Unknown. Most of these categories speak for themselves. Academic/Practitioner applications were submitted by doctors and/or academics unaffiliated with one specific organization fitting another category. Other refers to one specific item: erythropoiesis-stimulating agents. Unknown refers to those submissions where data is yet to be found.

Two medicines – bedaquiline in 2015 and sofosbuvir+velpatasvir in 2017 – were each separately submitted by both the manufacturer and the WHO. Therefore, each submission category was granted a 0.5 out of 1 in calculating percentages for those medicines.

There is a very high probability based on trends that the majority submissions categorized as “unknown” are from within the WHO itself, especially those in the categories of vitamins and minerals, vaccines, antiseptic/disinfectant, and 2017’s MDRs. However, there is no proof to confirm this assertion, therefore they were classified as unknown for the purposes of this paper.

Using the available information, percentages for submission categories were determined for the 19th and 20th EMLs. In phase 3, the data for use and submissions were simultaneously reviewed to determine totals and percentages for the 19th and 20th EMLs.

Appendix B:

Detailed List of Patent Information in Lower Income Countries

Abacavir

There are four jurisdictions with seven total active filings. The first date of expiration was 2009; the latest patent is set to expire in Brazil on February 5, 2028. Two patents are set to expire in 2020: BR9813048 is set to expire in Brazil on July 12, 2020, and MYPI9802147 on September 29, 2020, in Malaysia.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Belarus	1	13/05/2023	EA199900944	No
Brazil	3	5/2/2028	BR9809126	No
Kazakhstan	1	26/08/2022	EA199900944	No
Malaysia	2	28/12/2021	MYPI9804673	No

Adalimumab

There are 52 jurisdictions with 1,646 total active filings. The first date of expiration was 1989; the latest patent is set to expire in China on June 7, 2037. 32 patents are set to expire on March 27, 2020: 112015004984 in Brazil; 2015000574 in Chile; 104768576 in China, P2015000051 in the Dominican Republic; 20150047140 in Korea, DPR of; 2015003007 in Mexico; 09642015 in Peru; 35351 in Uruguay; and Eurasian Patent Office patents 029215, 201590518, and 201791717, in Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyz Republic, Russian Federation, Tajikistan, and Turkmenistan.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	33	2033-03-14	095325	Unknown (DPW)

Armenia	58	2033-03-26	201691542	Unknown (DPW)
Azerbaijan	58	2033-03-26	201691542	Unknown (DPW)
Belarus	58	2033-03-26	201691542	Unknown (DPW)
Benin	1	2021-02-15	13308	Unknown (DPW)
Brazil	103	2035-04-10	112017021809	Unknown (DPW)
Burkina Faso	1	2021-02-15	13308	Unknown (DPW)
Cameroon	1	2021-02-15	13308	Unknown (DPW)
Central African Republic	1	2021-02-15	13308	Unknown (DPW)
Chad	1	2021-02-15	13308	Unknown (DPW)
Chile	12	2032-02-13	2014002145	Unknown (DPW)
China	280	2037-06-07	108992673	Unknown (DPW)
Colombia	10	2031-08-01	6852079	Unknown (DPW)
Congo	1	2021-02-15	13308	Unknown (DPW)
Costa Rica	11	2031-08-01	20140031	Unknown (DPW)
Côte d'Ivoire	1	2021-02-15	13308	Unknown (DPW)
Cuba	3	2026-09-10	23791	Unknown (DPW)
Dominican Republic	9	2031-01-24	P2013000167	Unknown (DPW)
Ecuador	9	2031-01-24	SP13012820	Unknown (DPW)
El Salvador	1	2026-06-02	2008003113	Unknown (DPW)
Equatorial Guinea	1	2021-02-15	13308	Unknown (DPW)
Gabon	1	2021-02-15	13308	Unknown (DPW)
Georgia	2	2028-01-03	P20156390	Unknown (DPW)
Guatemala	3	2031-08-01	201400017	Unknown (DPW)
Guinea	1	2021-02-15	13308	Unknown (DPW)
Guinea-Bissau	1	2021-02-15	13308	Unknown (DPW)
Honduras	1	2026-06-02	2008001792	Unknown (DPW)
India	8	2032-02-15	5670DEN2014	Unknown (DPW)
Kazakhstan	58	2033-03-26	201691542	Unknown (DPW)
Korea, DPR of	232	2036-08-24	20190039580	Unknown (DPW)
Kyrgyz Republic	58	2033-03-26	201691542	Unknown (DPW)
Malaysia	13	2031-01-24	166835	Unknown (DPW)

Mali	1	2021-02-15	13308	Unknown (DPW)
Mauritania	1	2021-02-15	13308	Unknown (DPW)
Mexico	155	2034-05-23	361061	Unknown (DPW)
Montenegro	11	2030-11-11	02506	Unknown (DPW)
Morocco	7	2030-10-08	34646	Unknown (DPW)
Niger	1	2021-02-15	13308	Unknown (DPW)
Peru	20	2031-08-01	14092014	Unknown (DPW)
Philippines	5	2032-11-08	12015500986	Unknown (DPW)
Russian Federation	176	2034-05-23	2016150640	Unknown (DPW)
Senegal	1	2021-02-15	13308	Unknown (DPW)
Serbia	20	2034-05-23	57780	Unknown (DPW)
South Africa	59	2031-09-22	201508502	Unknown (DPW)
Tajikistan	58	2033-03-26	201691542	Unknown (DPW)
Togo	1	2021-02-15	13308	Unknown (DPW)
Tunisia	5	2030-10-08	2013000145	Unknown (DPW)
Turkey	3	2029-07-27	201908836	Unknown (DPW)
Turkmenistan	58	2033-03-26	201691542	Unknown (DPW)
Ukraine	19	2031-01-24	115423	Unknown (DPW)
Uruguay	13	2033-03-14	35444	Unknown (DPW)
Yugoslavia/Serbia and Montenegro	1	2021-10-11	37304	Unknown (DPW)

Aprepitant

There are 28 jurisdictions with 31 total active filings. The first date of expiration was 2013; the latest patents are set to expire in December 2022.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	1	8/12/2022	EP02796109	No
Algeria	1	8/12/2022	DZ040145	No
Belarus	2	8/12/2022	EA200400794	No

Brazil	2	8/12/2022	BRPI0214786	No
Chile	1	1/12/2022	CL200202791	No
China	1	8/12/2022	CN02827814	No
Colombia	1	8/12/2022	CO04054198	No
Georgia	1	8/12/2022	GEAP2002005622	No
India	1	8/12/2022	IN1265/CHENP/2004	No
Indonesia	1	8/12/2022	IDW00200401196	No
Jordan	1	2/12/2022	JOP20020126	No
Kazakhstan	1	8/12/2022	EA200400794	No
Malaysia	1	3/12/2022	MYPI20024570	No
Mexico	2	8/12/2022	MXPA2006/015183	No
Montenegro	1	8/12/2022	MEP68408	No
North Macedonia	1	8/12/2022	EP02796109	No
Pakistan	1	2/12/2022	PK1031/2002	No
Philippines	1	8/12/2022	PH12004500819	No
Russian Federation	1	8/12/2022	EA200400794	No
South Africa	1	7/12/2022	ZA200404012	No
Thailand	1	2/12/2022	TH0201004524	No
Turkey	1	8/12/2022	EP02796109	No
Ukraine	1	8/12/2022	UA20040705610	No
United Arab Emirates	1	8/12/2022	AE188/2004	No
Uzbekistan	1	8/12/2022	UZIAP20040271	No
Venezuela	1	4/12/2022	VE2002002393	No
Viet Nam	1	8/12/2022	VN1200400561	No
Yugoslavia/Serbia and Montenegro	1	8/12/2022	YUP50404	No

Atazanavir

There are 16 jurisdictions with 30 total active filings. The first date of expiration was 2017; the latest patent is set to expire in Brazil on May 13, 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	1	2/5/2025	ARP150100592	No
Brazil	3	13/05/2029	BRPI0509595	No
Chile	1	3/5/2025	CL200501057	No
China	4	2/5/2025	CN200580022550	No
India	3	2/5/2025	IN2933/DELNP/2009	Yes, MPP license
Lebanon	1	12/6/2028	LB8336	No
Mexico	5	19/06/2028	MX2009013504	No
Montenegro	1	2/5/2025	MEP20150653	No
Russian Federation	1	2/5/2025	RU2006142768	No
Serbia	1	2/5/2025	RSP20150653	No
South Africa	1	2/5/2025	ZA200609084	Yes, MPP license
Thailand	1	19/06/2028	TH0801003176	No
Turkey	4	19/06/2028	EP08771562	No
United Arab Emirates	1	21/06/2028	GCP2008011117	No
Venezuela	1	2/5/2025	VE2005-000854	No
Yugoslavia/Serbia and Montenegro	1	20/08/2022	YUP12204	No

Atazanavir + Ritonavir

There are two jurisdictions (Mexico and Thailand) with two total active filings for this specific combination patent, and both are set to expire June 19, 2028. However, there are 33 jurisdictions with 95 total active filings for patents related to atazanavir or ritonavir, individually, which affect this combination. The first date of expiration was 2012; the latest patent is set to expire in Brazil on May 13, 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	2	22/08/2024	AL/P/2011/3804	Commitment to not enforce ritonavir
Argentina	1	2/5/2025	ARP150100592	Commitment to not enforce ritonavir
Armenia	4	22/08/2024	EA200600473	Commitment to not enforce ritonavir

Azerbaijan	4	22/08/2024	EA201890737	Commitment to not enforce ritonavir
Belarus	4	22/08/2024	EA201301045	Commitment to not enforce ritonavir
Bosnia and Herzegovina	1	22/08/2024	BAP062383	Commitment to not enforce ritonavir
Brazil	5	13/05/2029	BRPI0509595	Commitment to not enforce ritonavir
Chile	2	23/05/2027	CL199901611	Commitment to not enforce ritonavir
China	7	2/5/2025	CN200580022550	Commitment to not enforce ritonavir
Ecuador	1	22/08/2024	ECSP066397	Commitment to not enforce ritonavir
India	3	2/5/2025	IN2933/DELNP/2009	Commitment to not enforce ritonavir; MPP license for atazanavir only
Indonesia	1	22/08/2024	ID200600560	Commitment to not enforce ritonavir
Kazakhstan	4	22/08/2024	EA200900292	Commitment to not enforce ritonavir
Kyrgyz Republic	4	22/08/2024	EA201890737	Commitment to not enforce ritonavir
Malaysia	2	12/1/2027	MYPI0402546	Commitment to not enforce ritonavir
Mexico	6	19/06/2028	MX2009013461	Commitment to not enforce ritonavir
Moldova, Republic of	4	22/08/2024	EA200600473	Commitment to not enforce ritonavir
Montenegro	3	2/5/2025	MEP20150653	Commitment to not enforce ritonavir
Nicaragua	1	22/08/2024	NI200600051	Commitment to not enforce ritonavir
North Macedonia	2	22/08/2024	MKP2011000220	Commitment to not enforce ritonavir
Philippines	1	14/03/2021	PH11993047529	Commitment to not enforce ritonavir
Russian Federation	5	2/5/2025	RU2006142768	Commitment to not enforce ritonavir
Serbia	2	2/5/2025	RSP20150653	Commitment to not enforce ritonavir
South Africa	4	2/5/2025	ZA200609084	Commitment to not enforce ritonavir; MPP licenses for atazanavir and ritonavir
Sri Lanka	1	22/08/2024	LK13996	Commitment to not enforce ritonavir
Tajikistan	3	22/08/2024	EA201301045	Commitment to not enforce ritonavir
Thailand	1	19/06/2028	TH0801003177	No
Turkey	9	2/5/2025	EP15180557	Commitment to not enforce ritonavir
Turkmenistan	4	22/08/2024	EA200900292	Commitment to not enforce ritonavir
Ukraine	1	22/08/2024	UAA200603276	Commitment to not enforce ritonavir
Venezuela	1	2/5/2025	VE2005-000854	Commitment to not enforce ritonavir
Viet Nam	1	22/08/2024	VN1200600476	Commitment to not

Azithromycin

There are 62 jurisdictions with 71 total active filings. The first date of expiration was 2019; the latest patents are set to expire December 4, 2023.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	1	2023-12-04	045630	Unknown (DPW)
Armenia	2	2023-12-04	010110	Unknown (DPW)
Azerbaijan	2	2023-12-04	010110	Unknown (DPW)
Belarus	2	2023-12-04	010110	Unknown (DPW)
Benin	1	2023-12-04	12858	Unknown (DPW)
Botswana	1	2023-12-04	2218	Unknown (DPW)
Brazil	1	2023-12-04	PI0403935	Unknown (DPW)
Burkina Faso	1	2023-12-04	12858	Unknown (DPW)
Cameroon	1	2023-12-04	12858	Unknown (DPW)
Central African Republic	1	2023-12-04	12858	Unknown (DPW)
Chad	1	2023-12-04	12858	Unknown (DPW)
Chile	1	2023-12-04	2004001501	Unknown (DPW)
China	1	2023-12-04	1697648	Unknown (DPW)
Congo	1	2023-12-04	12858	Unknown (DPW)
Costa Rica	1	2023-12-04	7500	Unknown (DPW)
Côte d'Ivoire	1	2023-12-04	12858	Unknown (DPW)
Dominican Republic	1	2023-12-04	P2004000994	Unknown (DPW)
Ecuador	1	2023-12-04	SP045351	Unknown (DPW)
Equatorial Guinea	1	2023-12-04	12858	Unknown (DPW)
Eswatini (formerly Swaziland)	1	2023-12-04	2218	Unknown (DPW)
Gabon	1	2023-12-04	12858	Unknown (DPW)
Gambia	1	2023-12-04	2218	Unknown (DPW)
Georgia	1	2023-12-04	P20074056	Unknown (DPW)

Ghana	1	2023-12-04	2218	Unknown (DPW)
Guatemala	1	2023-12-04	200400183	Unknown (DPW)
Guinea	1	2023-12-04	12858	Unknown (DPW)
Guinea-Bissau	1	2023-12-04	12858	Unknown (DPW)
Kazakhstan	2	2023-12-04	010110	Unknown (DPW)
Kenya	1	2023-12-04	2218	Unknown (DPW)
Korea, DPR of	2	2023-12-04	100906290	Unknown (DPW)
Kyrgyz Republic	2	2023-12-04	010110	Unknown (DPW)
Lesotho	1	2023-12-04	2218	Unknown (DPW)
Liberia	1	2023-12-04	2218	Unknown (DPW)
Malawi	1	2023-12-04	2218	Unknown (DPW)
Mali	1	2023-12-04	12858	Unknown (DPW)
Mauritania	1	2023-12-04	12858	Unknown (DPW)
Mexico	1	2023-12-04	PA04009424	Unknown (DPW)
Morocco	1	2023-12-04	27848	Unknown (DPW)
Mozambique	1	2023-12-04	2218	Unknown (DPW)
Namibia	1	2023-12-04	2218	Unknown (DPW)
Niger	1	2023-12-04	12858	Unknown (DPW)
Panama	1	2023-12-04	8611501	Unknown (DPW)
Peru	1	2023-12-04	20050573	Unknown (DPW)
Russian Federation	2	2023-12-04	010110	Unknown (DPW)
Rwanda	1	2023-12-04	2218	Unknown (DPW)
Sao Tome & Principe	1	2023-12-04	2218	Unknown (DPW)
Senegal	1	2023-12-04	12858	Unknown (DPW)
Serbia	1	2023-12-04	84704	Unknown (DPW)
Sierra Leone	1	2023-12-04	2218	Unknown (DPW)
Somalia	1	2023-12-04	2218	Unknown (DPW)
South Africa	1	2023-12-04	200408075	Unknown (DPW)
Sudan	1	2023-12-04	2218	Unknown (DPW)
Tajikistan	2	2023-12-04	010110	Unknown (DPW)
Tanzania, United Republic of	1	2023-12-04	2218	Unknown (DPW)

Togo	1	2023-12-04	12858	Unknown (DPW)
Tunisia	1	2023-12-04	SN05319	Unknown (DPW)
Turkmenistan	2	2023-12-04	010110	Unknown (DPW)
Uganda	1	2023-12-04	2218	Unknown (DPW)
Ukraine	1	2023-12-04	78793	Unknown (DPW)
Uruguay	1	2023-12-04	28509	Unknown (DPW)
Zambia	1	2023-12-04	2218	Unknown (DPW)
Zimbabwe	1	2023-12-04	2218	Unknown (DPW)

Bedaquiline

There are 71 jurisdictions with 249 active filings. The first date of expiration is set for July 2023; the latest patents are set to expire in the Russian Federation on October 21, 2028.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	1	2/12/2027	ALEP07847697	No
Argentina	1	23/07/2023	ARP030102655	No
Armenia	5	2/12/2027	EA200970532	Yes, bilateral license
Azerbaijan	5	2/12/2027	EA200970532	Yes, bilateral license
Belarus	5	2/12/2027	EA200970532	Yes, bilateral license
Benin	3	2/12/2027	OA1200900177	No
Bosnia and Herzegovina	1	17/07/2023	BA041930	No
Botswana	4	2/12/2027	AP200904870	No
Brazil	5	2/12/2027	BRPI0719693	No
Burkina Faso	3	2/12/2027	OA1200900177	No
Cameroon	3	2/12/2027	OA1200900177	No
Central African Republic	3	2/12/2027	OA1200900177	No
Chad	3	2/12/2027	OA1200900177	No
Chile	4	2/12/2027	CL2007003472	No
China	6	2/12/2027	CN201510368829	No
Congo	3	2/12/2027	OA1200900177	No

Côte d'Ivoire	3	2/12/2027	OA1200900177	No
Egypt	2	2/12/2027	EGPCT/824/2009	No
Equatorial Guinea	3	2/12/2027	OA1200900177	No
Eswatini (formerly Swaziland)	4	2/12/2027	AP200904870	No
Gabon	3	2/12/2027	OA1200900177	No
Gambia	4	2/12/2027	AP200904870	No
Ghana	4	2/12/2027	AP200904870	No
Guinea	3	2/12/2027	OA1200900177	No
Guinea-Bissau	3	2/12/2027	OA1200900177	No
India	4	2/12/2027	IN1220/MUMNP/2009	No
Indonesia	3	11/3/2027	IDW00200901493	No
Jordan	3	1/12/2027	JOP20070511	No
Kazakhstan	5	2/12/2027	EA200970532	Yes, bilateral license
Kenya	4	2/12/2027	AP200904870	No
Kosovo	3	10/8/2028	KV2008048	No
Kyrgyz Republic	5	2/12/2027	EA200970532	Yes, bilateral license
Lebanon	2	3/12/2027	LB200708103	No
Lesotho	4	2/12/2027	AP200904870	No
Malawi	4	2/12/2027	AP200904870	No
Malaysia	4	2/12/2027	MYPI20092284	No
Mali	3	2/12/2027	OA1200900177	No
Mauritania	3	2/12/2027	OA1200900177	No
Mexico	4	2/12/2027	MX2009005909	No
Moldova, Republic of	5	2/12/2027	EA200970532	Yes, bilateral license
Montenegro	5	2/12/2027	MEP9512	No
Mozambique	4	2/12/2027	AP200904870	No
Namibia	3	2/12/2027	AP200904870	No
Nicaragua	1	4/6/2027	NI200700146	No
Niger	3	2/12/2027	OA1200900177	No
Pakistan	5	2/12/2027	PK1403/2007	No
Panama	3	4/12/2027	PA87597	No

Peru	1	4/12/2027	PE2007001719	No
Philippines	4	2/12/2027	PH12009500858	No
Russian Federation	5	21/10/2028	EA200602260	Yes, bilateral license
Senegal	3	2/12/2027	OA1200900177	No
Serbia	3	2/12/2027	RSP20120336	No
Sierra Leone	4	2/12/2027	AP200904870	No
South Africa	5	2/12/2027	ZA200903907	No
Sri Lanka	3	2/12/2027	LK15376	No
Sudan	4	2/12/2027	AP200904870	No
Tajikistan	5	2/12/2027	EA200970532	Yes, bilateral license
Tanzania, United Republic of	4	2/12/2027	AP200904870	No
Thailand	3	1/12/2027	TH0701006189	No
Togo	3	2/12/2027	OA1200900177	No
Turkey	6	2/12/2027	EP07847697	No
Turkmenistan	5	2/12/2027	EA200970532	Yes, bilateral license
Uganda	4	2/12/2027	AP200904870	No
Ukraine	5	2/12/2027	UAA200904218	Yes, bilateral license
United Arab Emirates	3	4/12/2027	GC200709625	No
Uruguay	1	4/12/2027	UY30762	No
Venezuela	2	5/12/2027	VE2007002659	No
Viet Nam	3	2/12/2027	VN1200900771	No
Yugoslavia/Serbia and Montenegro	1	17/07/2023	YUP20050058	No
Zambia	4	2/12/2027	AP200904870	No
Zimbabwe	4	2/12/2027	AP200904870	No

Bendamustine

There are 23 jurisdictions with 40 active filings. The first dates of expiration are set for January 2026; the latest patents are set to expire September 22, 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
---------	--------------------------	-------------------------	---------------	--------------------------------

Albania	3	25/03/2029	EP09723661	No
Armenia	1	12/1/2026	EA200701511	No
Azerbaijan	1	12/1/2026	EA200701511	No
Belarus	1	12/1/2026	EA200701511	No
Bosnia and Herzegovina	3	25/03/2029	EP09723661	No
Brazil	1	12/1/2026	BRPI0606332	No
Chile	1	12/1/2026	CL200600074	No
China	5	22/09/2029	CN200980137977	No
Egypt	1	12/1/2026	EG2007000689	No
Kazakhstan	1	12/1/2026	EA200701511	No
Kyrgyz Republic	1	12/1/2026	EA200701511	No
Malaysia	1	12/1/2026	MYPI20060159	No
Mexico	4	22/09/2029	MX2011002936	No
Moldova, Republic of	1	12/1/2026	EA200701511	No
North Macedonia	3	22/09/2029	EP15152744	No
Philippines	1	12/1/2026	PH12007501445	No
Russian Federation	1	12/1/2026	EA200701511	No
Serbia	3	22/09/2029	EP15152744	No
South Africa	1	12/1/2026	ZA200705793	No
Tajikistan	1	12/1/2026	EA200701511	No
Turkey	3	22/09/2029	EP15152744	No
Turkmenistan	1	12/1/2026	EA200701511	No
Ukraine	1	12/1/2026	UAA200709242	No

Bortezomib

There is one jurisdiction with four active filings. The first date of expiration was 2015; all remaining, active patents are set to expire in Turkey on January 24, 2022. Of these four remaining patents, one status is listed as “granted,” one status is listed as “granted and opposed,” and two are listed as “filed.”

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Turkey	4	2022-1-24	EP10006835	No

Budesonide + Formoterol

There are 13 jurisdictions with 67 total active filings. The first date of expiration is set for 2022; the latest patents are set to expire April 14, 2025.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	5	2025-04-14	055910	Unknown (DPW)
Brazil	6	2025-04-14	PI0609459	Unknown (DPW)
China	11	2025-04-14	101198972	Unknown (DPW)
Colombia	1	2022-02-01	5611098	Unknown (DPW)
Egypt	2	2025-04-14	25113	Unknown (DPW)
Korea, DPR of	14	2025-04-14	20080003343	Unknown (DPW)
Malaysia	3	2025-04-14	143551	Unknown (DPW)
Mexico	5	2025-04-14	2007012539	Unknown (DPW)
Russian Federation	6	2025-04-14	2388052	Unknown (DPW)
South Africa	6	2025-04-14	200708220	Unknown (DPW)
Turkey	1	2024-07-05	201809758	Unknown (DPW)
Ukraine	3	2025-04-14	90709	Unknown (DPW)
Uruguay	4	2025-04-14	29474	Unknown (DPW)

Carbetocin

There are 16 jurisdictions with 25 active filings. The first date of expiration is set for September 27, 2031; the latest patents are set to expire November 28, 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	1	28/09/2031	EP17169301	No
Algeria	1	28/09/2031	DZ130183	No

Argentina	1	28/09/2031	AR20110103594	No
Bosnia and Herzegovina	1	28/09/2031	EP17169301	No
Brazil	1	28/09/2031	BR112013007362	No
China	3	28/09/2031	CN201610930541	No
India	1	28/09/2031	IN2471/DELNP/2013	No
Jordan	3	27/09/2031	JOP20110297	No
Mexico	4	28/11/2031	MX2016014747	No
Montenegro	1	28/09/2031	EP17169301	No
North Macedonia	1	28/09/2031	EP17169301	No
Russian Federation	2	28/09/2031	RU2016143751	No
Serbia	2	28/09/2031	EP17169301	No
South Africa	1	28/09/2031	ZA201301991	No
Turkey	1	28/09/2031	EP17169301	No
United Arab Emirates	1	28/09/2031	AEP328/2013	No

Ceftazidime + Avibactam

There are no patents specifically for this combination; all active patents are related to either ceftazidime or avibactam individually. There are 73 jurisdictions with 147 total active filings relevant to the compounds that make up this combination. The first date of expiration was 1999; the latest patent is set to expire in Bosnia and Herzegovina on January 26, 2033.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	5	7/10/2030	EP19151839	No
Algeria	2	26/01/2023	DZ040194	No
Argentina	3	14/06/2032	ARP120102159	No
Belize	1	23/07/2021	BZ323.03	No
Benin	2	26/01/2023	OA1200400200	No
Bolivia	1	26/01/2023	BO230015	No
Bosnia and Herzegovina	3	26/01/2033	BA041758	No
Brazil	5	14/06/2032	BR112013032415	No

Burkina Faso	2	26/01/2023	OA1200400200	No
Cameroon	2	26/01/2023	OA1200400200	No
Central African Republic	2	26/01/2023	OA1200400200	No
Chad	2	26/01/2023	OA1200400200	No
Chile	2	16/06/2026	CL200300134	No
China	7	14/06/2032	CN201280029765	No
Colombia	1	23/07/2021	CO03006082	No
Congo	2	26/01/2023	OA1200400200	No
Costa Rica	3	26/01/2023	CR7387	No
Côte d'Ivoire	2	26/01/2023	OA1200400200	No
Ecuador	1	14/07/2024	ECSP045193	No
Egypt	1	25/01/2023	EG2003000062	No
Equatorial Guinea	2	26/01/2023	OA1200400200	No
Eswatini (formerly Swaziland)	1	23/07/2021	AP200302726	No
Fiji	1	26/01/2023	FJ03709903.3	No
Gabon	2	26/01/2023	OA1200400200	No
Gambia	2	26/01/2023	GMPI20015	No
Ghana	1	23/07/2021	AP200302726	No
Grenada	1	26/01/2023	GD03709903.3	No
Guinea	2	26/01/2023	OA1200400200	No
Guinea-Bissau	2	26/01/2023	OA1200400200	No
India	4	7/10/2030	IN586/MUMNP/2012	No
Indonesia	2	26/01/2023	IDW00200401585	No
Jordan	1	28/12/2022	JOP20020138	No
Kenya	2	26/01/2023	KEPCT/FR03/00243	No
Kiribati	1	26/01/2023	KI25/13	No
Lebanon	1	2/1/2023	LB6630	No
Lesotho	1	23/07/2021	AP200302726	No
Malawi	1	23/07/2021	AP200302726	No
Malaysia	3	14/06/2032	MYPI2013702441	No
Mali	2	26/01/2023	OA1200400200	No

Mauritania	2	26/01/2023	OA1200400200	No
Mexico	4	14/06/2032	MX2013014114	No
Montenegro	3	7/10/2030	EP17182561	No
Morocco	2	26/01/2023	MA27777	No
Mozambique	1	23/07/2021	AP200302726	No
Niger	2	26/01/2023	OA1200400200	No
Nigeria	1	15/01/2023	NG35/2003	No
North Macedonia	5	7/10/2030	EP17182561	No
Pakistan	1	26/01/2023	PK00492003	No
Paraguay	1	26/01/2023	PY1561/2003	No
Peru	1	26/01/2023	PE2003000080	No
Philippines	1	26/01/2023	PH12004501030	No
Russian Federation	6	14/06/2032	RU2017102358	No
Samoa	1	26/01/2023	WS03709903.3	No
Senegal	2	26/01/2023	OA1200400200	No
Serbia	1	7/10/2030	EP19151839	No
Sierra Leone	1	23/07/2021	AP200302726	No
South Africa	2	26/01/2023	ZA200405607	No
Sudan	1	23/07/2021	AP200302726	No
Tanzania, United Republic of	1	23/07/2021	AP200302726	No
Thailand	1	23/01/2023	TH0301000234	No
Togo	2	26/01/2023	OA1200400200	No
Tunisia	1	22/07/2024	TNSN04137	No
Turkey	8	14/06/2032	EP12727922	No
Turks and Caicos Islands	1	26/01/2023	TC03709903.3	No
Uganda	1	23/07/2021	AP200302726	No
Ukraine	2	26/01/2023	UA20040807144	No
United Arab Emirates	2	26/01/2023	AEPCT/FR03/00243	No
Uruguay	1	26/01/2023	UY27626	No
Venezuela	2	27/01/2023	VE19970003	No
Viet Nam	2	26/01/2023	VN1200400849	No

Virgin Islands (British)	1	26/01/2023	VG03709903.3	No
Yugoslavia/Serbia and Montenegro	2	26/01/2023	YUP65804	No
Zimbabwe	1	23/07/2021	AP200302726	No

Dabigatran

There are 28 jurisdictions with 70 total active filings. The first date of expiration was 2018; the latest patent is set to expire in Chile on September 28, 2029. Patent BR9807843 is set to expire in Brazil on June 28, 2020.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	1	6/3/2023	ARP030100779	No
Belarus	2	15/12/2025	EA200701208	No
Brazil	3	15/12/2025	BRPI0519727	No
Chile	2	28/09/2029	CL2009001915	No
China	3	23/08/2024	CN200480024952	No
Colombia	2	15/12/2025	CO07064847	No
Egypt	3	15/12/2025	EG2007000618	No
India	4	15/12/2025	IN4625/DELNP/2007	No
Indonesia	2	15/12/2025	IDW00200701940	No
Kazakhstan	1	15/02/2023	EA199900746	No
Kyrgyz Republic	1	15/02/2023	EA199900746	No
Malaysia	2	4/3/2023	MYPI20030780	No
Mexico	3	15/12/2025	MX2007007464	No
Montenegro	2	23/08/2024	MEP50608	No
Pakistan	3	28/08/2023	PK06592004	No
Peru	2	4/3/2023	PE2007000159	No
Philippines	4	15/12/2025	PH12007501306	No
Russian Federation	3	15/12/2025	EA200701208	No
Serbia	1	23/08/2024	RSP20060136	No
South Africa	3	15/12/2025	ZA200704195	No

Thailand	2	26/08/2024	TH0401003346	No
Turkey	3	23/08/2024	EP04764411	No
Ukraine	5	15/12/2025	UAA200708133	No
United Arab Emirates	3	15/12/2025	AE20070513	No
Uzbekistan	2	2/3/2023	UZ20040374	No
Venezuela	2	26/08/2024	VE20041396	No
Viet Nam	4	15/12/2025	VN1200701462	No
Yugoslavia/Serbia and Montenegro	2	23/08/2024	YUP20060136	No

Daclatasvir

There are 16 jurisdictions with 46 total active filings. The first date of expiration is set for August 2027; the latest patents are set to expire in 2030.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	3	7/8/2028	ARP080103487	No
Brazil	4	1/11/2030	BR112012011134	No
Chile	3	7/8/2028	CL2008002354	Commitment to not enforce
China	5	1/11/2030	CN201080061158	No
Colombia	3	1/11/2030	CO12075545	Commitment to not enforce
India	3	1/11/2030	IN3999/CHENP/2012	Yes, MPP license
Lebanon	1	8/8/2027	LB200707962	No
Mexico	4	1/11/2030	MX2012005246	Commitment to not enforce
Pakistan	1	8/8/2027	PK0954/07	Yes, MPP license
Peru	2	7/8/2028	PE2008001326	Commitment to not enforce
Russian Federation	4	1/11/2030	EA201270616	No
South Africa	2	30/07/2028	ZA201000843	Yes, MPP license
Thailand	2	7/8/2028	TH0801004156	No
Turkey	5	30/07/2028	EP08796910	No
United Arab Emirates	2	8/8/2028	GC2008011478	No
Venezuela	2	5/8/2028	VE200801614	Commitment to not enforce

Dasabuvir

There are 17 jurisdictions with 34 total active filings. The first date of expiration is set for 2028; the latest patents are set to expire in 2033.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	1	17/10/2033	EP13789411	No
Armenia	2	17/10/2033	EA201791354	No
Azerbaijan	2	17/10/2033	EA201791354	No
Belarus	2	17/10/2033	EA201590752	No
Brazil	1	17/10/2033	BR112015008927	No
China	4	17/10/2033	CN201811208736	No
Kazakhstan	2	17/10/2033	EA201590752	No
Kyrgyz Republic	2	17/10/2033	EA201590752	No
Mexico	2	17/10/2033	MX2015004973	No
North Macedonia	1	17/10/2033	EP13789411	No
Russian Federation	4	17/10/2033	EA201590752	No
Serbia	1	17/10/2033	EP13789411	No
South Africa	1	16/09/2028	ZA201002689	No
Tajikistan	2	17/10/2033	EA201590752	No
Turkey	4	17/10/2033	EP13789411	No
Turkmenistan	2	17/10/2033	EA201590752	No
Ukraine	1	16/09/2028	UA2010004147	No

Dasatinib

There are 19 jurisdictions with 37 total active filings. The first date of expiration is set for April 2020; the latest patent is set to expire in Brazil on November 20, 2028. Eight patents are set to expire on April 11, 2020: EP17167936 in Albania, IN/PCT/2001/01138/MUM in India, MXPA01010292 in Mexico, EP17167936 in North Macedonia, RU2005107463 and

RU2001130452 in the Russian Federation, ZA200107204 in South Africa, and TR200102969 in Turkey.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	2	3/2/2025	EP05722772	No
Bosnia and Herzegovina	1	3/2/2025	EP05722772	No
Brazil	2	20/11/2028	BRPI0009721	No
China	1	3/2/2025	CN200580011916	No
Georgia	2	3/2/2025	GEAP2009009607	No
India	2	3/2/2025	IN6567DEN2014	No
Malaysia	1	9/3/2024	MYP120040834	No
Mexico	4	3/11/2025	MX/a/2007/005115	No
North Macedonia	2	3/2/2025	EP05722772	No
Peru	2	3/2/2025	PE2005000128	No
Russian Federation	4	3/2/2025	RU2006131591	No
Serbia	1	3/2/2025	EP05722772	No
South Africa	3	3/2/2025	ZA200606242	No
Thailand	2	3/2/2025	TH0501000446	No
Turkey	3	3/2/2025	EP05722772	No
Ukraine	1	22/03/2024	UAA200509996	No
Venezuela	1	3/2/2025	VE2005000208	No
Viet Nam	2	3/2/2025	VN1200601461	No
Yugoslavia/Serbia and Montenegro	1	22/03/2024	YUP69805	No

Delamanid

There are 24 jurisdictions with 49 total active filings. The first date of expiration is set for 2023; the latest patents are set to expire in 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	1	8/10/2023	ARP030103673	No
Armenia	1	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)

Azerbaijan	1	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)
Bangladesh	2	4/10/2026	BD20060220	Yes, bilateral license (Mylan)
Belarus	3	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)
Brazil	2	18/07/2026	BRPI0613883	Yes, bilateral license (Mylan)
China	4	27/01/2031	CN201180006814	No
India	3	3/10/2026	IN1255/KOLNP/2008	Yes, bilateral license (Mylan)
Indonesia	1	18/07/2026	ID00200800233	No
Kazakhstan	1	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)
Kyrgyz Republic	1	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)
Malaysia	2	25/07/2026	MYPI20063579	Yes, bilateral license (Mylan)
Mexico	3	27/01/2031	MX2012008501	Yes, bilateral license (Mylan)
Moldova, Republic of	1	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)
Pakistan	2	2/10/2026	PK200601314	Yes, bilateral license (Mylan)
Philippines	3	25/11/2027	PH12007502673	No
Russian Federation	4	12/7/2031	RU2011129167	Yes, bilateral license (R-Pharm)
South Africa	4	27/01/2031	ZA201204802	Yes, bilateral license (Mylan)
Tajikistan	1	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)
Thailand	2	2/10/2026	TH0601004877	No
Turkey	3	27/01/2031	EP11706939	No
Turkmenistan	1	27/01/2031	EA201290681	Yes, bilateral license (R-Pharm)
Ukraine	2	18/07/2026	UAA200802496	Yes, bilateral license (R-Pharm)
Viet Nam	1	18/07/2026	VN200800490	No

Dolutegravir

There are 26 jurisdictions with 54 active filings. The first date of expiration is set for 2026; the latest patent is set to expire in Armenia on April 27, 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Algeria	1	27/04/2026	DZ070738	No
Armenia	1	27/04/2031	EA200702080	Yes, MPP and bilateral licenses

Azerbaijan	1	13/12/2026	EA200702080	No
Belarus	1	30/09/2030	EA200702080	No
Brazil	2	7/12/2029	BRPI0923217	No
China	9	8/12/2029	CN201710119973	No
Colombia	1	27/04/2026	CO07115501	No
Egypt	1	27/04/2026	EG2007011167	Yes, MPP and bilateral licenses
India	5	8/12/2029	IN1971/KOLNP/2011	Yes, MPP and bilateral licenses
Indonesia	3	7/12/2029	IDP0020140377	Yes, MPP and bilateral licenses
Kazakhstan	1	3/2/2030	EA200702080	No
Kyrgyz Republic	1	27/04/2026	EA200702080	Yes, MPP and bilateral licenses
Malaysia	1	30/10/2027	MY200701883	No
Mexico	4	7/12/2029	MX2013008013	No
Moldova, Republic of	1	22/04/2030	EA200702080	Yes, MPP and bilateral licenses
Morocco	1	27/04/2026	MA30388	Yes, MPP and bilateral licenses
Nigeria	1	27/04/2026	NG2007/12/473	Yes, MPP and bilateral licenses
Philippines	1	27/04/2026	PH12007502373	Yes, MPP and bilateral licenses
Russian Federation	3	7/12/2029	RU2013153004	No
South Africa	1	27/04/2026	ZA200708970	Yes, MPP and bilateral licenses
Tajikistan	1	27/04/2026	EA200702080	Yes, MPP and bilateral licenses
Trinidad and Tobago	1	27/04/2026	TT200700254	No
Turkey	8	7/12/2029	EP09832226	No
Turkmenistan	1	27/04/2026	EA200702080	Yes, MPP and bilateral licenses
Ukraine	1	27/04/2026	UAA200711345	Yes, MPP and bilateral licenses
Viet Nam	2	27/04/2026	VN201300151	Yes, MPP and bilateral licenses

Dolutegravir + Lamivudine + Tenofovir

There are 26 jurisdictions with 54 active filings. The first date of expiration was 2017; the latest patent is set to expire in Armenia on April 27, 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
---------	--------------------------	-------------------------	---------------	--------------------------------

Algeria	1	27/04/2026	DZ070738	No
Armenia	1	27/04/2031	EA200702080	Yes, MPP and bilateral licenses
Azerbaijan	1	13/12/2026	EA200702080	No
Belarus	1	30/09/2030	EA200702080	No
Brazil	2	7/12/2029	BRPI0923217	No
China	9	8/12/2029	CN201710119972	No
Colombia	1	27/04/2026	CO07115501	No
Egypt	1	27/04/2026	EG2007011167	Yes, MPP and bilateral licenses
India	5	8/12/2029	IN1971/KOLNP/2011	Yes, MPP and bilateral licenses
Indonesia	3	7/12/2029	IDP0020140377	Yes, MPP and bilateral licenses
Kazakhstan	1	3/2/2030	EA200702080	No
Kyrgyz Republic	1	27/04/2026	EA200702080	Yes, MPP and bilateral licenses
Malaysia	1	30/10/2027	MY200701883	No
Mexico	4	7/12/2029	MX2013008013	No
Moldova, Republic of	1	22/04/2030	EA200702080	Yes, MPP and bilateral licenses
Morocco	1	27/04/2026	MA30388	Yes, MPP and bilateral licenses
Nigeria	1	27/04/2026	NG2007/12/473	Yes, MPP and bilateral licenses
Philippines	1	27/04/2026	PH12007502373	Yes, MPP and bilateral licenses
Russian Federation	3	7/12/2029	RU2013153004	No
South Africa	1	27/04/2026	ZA200708970	Yes, MPP and bilateral licenses
Tajikistan	1	27/04/2026	EA200702080	Yes, MPP and bilateral licenses
Trinidad and Tobago	1	27/04/2026	TT200700254	No
Turkey	8	7/12/2029	EP09832226	No
Turkmenistan	1	27/04/2026	EA200702080	Yes, MPP and bilateral licenses
Ukraine	1	27/04/2026	UAA200711345	Yes, MPP and bilateral licenses
Viet Nam	2	27/04/2026	VN201300151	Yes, MPP and bilateral licenses

Efavirenz

There are two jurisdictions with two total active filings. The first date of expiration was 2011; the latest patent (EA199900944) is set to expire in Belarus on September 20, 2021. The other active patent (ZA200004313) is set to expire in South Africa in 2020.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Belarus	1	20/09/2021	EA199900720	No
South Africa	1	21/08/2020	ZA200004313	No

Efavirenz + Emtricitabine + Tenofovir

There are 16 jurisdictions with 45 active filings. The first date of expiration was 2009; the latest patent is set to expire in Russian Federation on June 12, 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Expiration	Subject to Licensing Agreement
Armenia	3	12/6/2026	EA201201265	Commitment to not enforce; MPP and bilateral licenses on TDF
Azerbaijan	3	12/6/2026	EA200800033	MPP license on TDF only
Belarus	4	12/6/2026	EA201201265	Commitment to not enforce; MPP license on TDF
China	5	12/6/2026	CN200680026180	No
Kazakhstan	3	12/6/2026	EA201201265	Commitment to not enforce; MPP and bilateral licenses on TDF
Kyrgyz Republic	3	12/6/2026	EA201201265	Commitment to not enforce; MPP and bilateral licenses on TDF
Mexico	2	12/6/2026	MX2007015764	No
Moldova, Republic of	3	12/6/2026	EA201201265	Commitment to not enforce; MPP and bilateral licenses on TDF

Russian Federation	3	12/6/2031	EA200800033	No
South Africa	1	12/6/2026	ZA200800297	Commitment to not enforce; MPP and bilateral licenses on TDF
Tajikistan	3	12/6/2026	EA201201265	Commitment to not enforce; MPP and bilateral licenses on TDF
Turkey	5	12/6/2026	EP15154733	No
Turkmenistan	3	12/6/2026	EA200800033	Commitment to not enforce; MPP and bilateral licenses on TDF
Ukraine	2	12/6/2026	UAA200800493	Commitment to not enforce; MPP license on TDF
Venezuela	1	12/6/2026	VE2006-001299	No
Viet Nam	1	12/1/2024	VN1200500812	Commitment to not enforce; MPP and bilateral licenses on TDF

Emtricitabine + Tenofovir

There are 14 jurisdictions with 17 total active filings. All active filings for this specific combination are set to expire January 12, 2024.

Country	Number of Active Filings	Date of Last Expiration	Patent Expiration	Subject to Licensing Agreement
Armenia	1	12/1/2024	EA201100293	Commitment to not enforce; MPP and bilateral licenses on TDF
Azerbaijan	1	12/1/2024	EA201100293	MPP license on TDF only
Belarus	1	12/1/2024	EA201100293	Commitment to not enforce; MPP license on TDF
China	3	12/1/2024	CN201510697340	No
Kazakhstan	1	12/1/2024	EA201100293	Commitment to not enforce; MPP and bilateral licenses on TDF

Kyrgyz Republic	1	12/1/2024	EA201100293	Commitment to not enforce; MPP and bilateral licenses on TDF
Mexico	1	12/1/2024	MXPA05007016	No
Moldova, Republic of	1	12/1/2024	EA201100293	Commitment to not enforce; MPP and bilateral licenses on TDF
Russian Federation	1	12/1/2024	EA201100293	No
Tajikistan	1	12/1/2024	EA201100293	Commitment to not enforce; MPP and bilateral licenses on TDF
Turkey	2	12/1/2024	TR2008/06970	No
Turkmenistan	1	12/1/2024	EA201100293	Commitment to not enforce; MPP and bilateral licenses on TDF
Ukraine	1	12/1/2024	UA2005007947	Commitment to not enforce; MPP license on TDF
Viet Nam	1	12/1/2024	VN1200500812	Commitment to not enforce; MPP and bilateral licenses on TDF

Erlotinib

There are 44 jurisdictions with 62 active filings. The first date of expiration was 2005; the latest patents are set to expire in 2024. 52 of the active filings are set to expire in 2020.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	2	8/11/2020	EP00980346	No
Armenia	1	8/11/2020	EA200200546	No
Azerbaijan	1	8/11/2020	EA200200546	No
Belarus	1	8/11/2020	EA200200546	No
Bosnia and Herzegovina	1	8/11/2020	BA021081A	No
Brazil	3	10/2/2024	BRPI0407520	No
Chile	2	9/11/2020	CL2010000616	No
China	2	10/2/2024	CN200480004381	No
Eswatini (formerly Swaziland)	1	8/11/2020	AP200202542	No

Gambia	1	8/11/2020	AP200202542	No
Georgia	1	8/11/2020	GEAP2000004833	No
Ghana	1	8/11/2020	AP200202542	No
India	3	10/2/2024	IN1900/CHENP/2005	No
Indonesia	1	8/11/2020	IDW00200201337	No
Kazakhstan	1	8/11/2020	EA200200546	No
Kenya	1	8/11/2020	AP200202542	No
Kyrgyz Republic	1	8/11/2020	EA200200546	No
Lesotho	1	8/11/2020	AP200202542	No
Malawi	1	8/11/2020	AP200202542	No
Malaysia	1	29/03/2022	MYP120005272	No
Mexico	2	10/2/2024	MXPA05008598	No
Moldova, Republic of	1	8/11/2020	EA200200546	No
Montenegro	2	8/11/2020	MEP36308	No
Morocco	1	8/11/2020	MA26677	No
Mozambique	1	8/11/2020	AP200202542	No
North Macedonia	2	8/11/2020	EP10185615	No
Philippines	2	10/2/2024	PH12005501493	No
Russian Federation	3	10/2/2024	RU2005128774	No
Sierra Leone	1	8/11/2020	AP200202542	No
South Africa	2	10/2/2024	ZA200506339	No
Sri Lanka	1	8/11/2020	LK12751	No
Sudan	1	8/11/2020	AP200202542	No
Tajikistan	1	8/11/2020	EA200200546	No
Tanzania, United Republic of	1	8/11/2020	AP200202542	No
Turkey	4	10/2/2024	EP04710031	No
Turkmenistan	1	8/11/2020	EA200200546	No
Uganda	1	8/11/2020	AP200202542	No
Ukraine	2	8/11/2020	UA2002064754	No
Uzbekistan	1	8/11/2020	UZIAP20020397	No
Venezuela	1	7/11/2020	VE2501-00	No

Viet Nam	1	8/11/2020	VN1200200373	No
Yugoslavia/Serbia and Montenegro	1	8/11/2020	YUP34202	No
Zambia	1	8/11/2020	AP200202542	No
Zimbabwe	1	8/11/2020	AP200202542	No

Etonogestrel-Releasing Implant

There are 12 jurisdictions with 36 active filings. The first date of expiration is set for 2024; the latest patents are set to expire in January 2025.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	3	2025-01-24	056923	Unknown (DPW)
Brazil	3	2025-01-24	PI0607013	Unknown (DPW)
China	3	2025-01-24	101151062	Unknown (DPW)
Ecuador	1	2024-03-19	SP066865	Unknown (DPW)
Egypt	1	2024-03-19	24359	Unknown (DPW)
Korea, DPR of	6	2025-01-24	20070112144	Unknown (DPW)
Malaysia	1	2024-03-19	142649	Unknown (DPW)
Mexico	3	2025-01-24	2007008881	Unknown (DPW)
Peru	3	2025-01-24	20061225	Unknown (DPW)
Russian Federation	6	2025-01-24	2361628	Unknown (DPW)
South Africa	3	2025-01-24	200705962	Unknown (DPW)
Ukraine	3	2025-01-24	89518	Unknown (DPW)

Fexinidazole

There are 27 jurisdictions with 95 active filings. The first date of expiration is set for 2024; the latest patents are set to expire in 2036.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Botswana	3	2032-11-22	3759	Unknown (DPW)
Brazil	2	2035-04-09	112017021380	Unknown (DPW)

China	21	2036-05-05	107847398	Unknown (DPW)
Costa Rica	1	2032-11-22	20150286	Unknown (DPW)
Eswatini (formerly Swaziland)	3	2032-11-22	3759	Unknown (DPW)
Gambia	3	2032-11-22	3759	Unknown (DPW)
Ghana	3	2032-11-22	3759	Unknown (DPW)
Kenya	3	2032-11-22	3759	Unknown (DPW)
Korea, DPR of	6	2036-05-05	20180135975	Unknown (DPW)
Lesotho	3	2032-11-22	3759	Unknown (DPW)
Liberia	3	2032-11-22	3759	Unknown (DPW)
Malawi	3	2032-11-22	3759	Unknown (DPW)
Mexico	4	2035-04-09	2017012759	Unknown (DPW)
Mozambique	3	2032-11-22	3759	Unknown (DPW)
Namibia	3	2032-11-22	3759	Unknown (DPW)
Russian Federation	1	2035-04-09	2017134285	Unknown (DPW)
Rwanda	3	2032-11-22	3759	Unknown (DPW)
Sao Tome & Principe	3	2032-11-22	3759	Unknown (DPW)
Serbia	1	2033-01-31	57469	Unknown (DPW)
Sierra Leone	3	2032-11-22	3759	Unknown (DPW)
Somalia	3	2032-11-22	3759	Unknown (DPW)
South Africa	2	2032-11-22	201503063	Unknown (DPW)
Sudan	3	2032-11-22	3759	Unknown (DPW)
Tanzania, United Republic of	3	2032-11-22	3759	Unknown (DPW)
Uganda	3	2032-11-22	3759	Unknown (DPW)
Zambia	3	2032-11-22	3759	Unknown (DPW)
Zimbabwe	3	2032-11-22	3759	Unknown (DPW)

Glecaprevir + Pibrentasvir

There are 44 jurisdictions with 253 active filings. The first date of expiration is set for 2031; the latest patent is set to expire in Brazil on February 14, 2038.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	8	17/10/2037	EP17196993	No
Argentina	2	11/10/2031	ARP110103777	No
Armenia	7	23/06/2036	EA201890160	No
Azerbaijan	7	23/06/2036	EA201890160	No
Belarus	8	17/07/2036	EA201890334	No
Bolivia	4	11/10/2031	BO201100314F1	Yes, MPP license
Bosnia and Herzegovina	8	17/10/2037	EP17196993	No
Brazil	8	14/02/2038	BR102018002956	No
Chile	5	17/07/2036	CL2018000138	No
China	16	12/2/2038	CN201810149405	No
Colombia	4	17/07/2036	CO2018000391	No
Costa Rica	5	17/07/2036	CR20180088	No
Dominican Republic	6	17/07/2036	DO2018000024	No
Ecuador	3	11/10/2031	ECSP14012622	No
Egypt	5	17/07/2036	EG2018000084	Yes, MPP license
Guatemala	2	11/10/2031	GT201300093A	No
India	5	17/07/2036	IN201817004313	No
Indonesia	3	17/07/2036	IDP201801161	Yes, MPP license
Kazakhstan	8	17/07/2036	EA201890334	No
Kyrgyz Republic	7	23/06/2036	EA201890160	No
Malaysia	2	11/10/2031	MYPI2013700273	No
Mexico	11	17/07/2036	MX2018000746	No
Moldova, Republic of	6	17/10/2037	EP17196993	No
Mongolia	2	11/10/2031	MN2011005013	No
Montenegro	8	17/10/2037	EP17196993	No
Morocco	2	17/10/2037	EP17196993	Yes, MPP license
North Macedonia	8	17/10/2037	EP17196993	No
Pakistan	3	11/10/2031	PK2011000752	Yes, MPP license
Panama	2	12/10/2031	PA8945601	No
Paraguay	2	11/10/2031	PY2011043679	No

Peru	5	17/07/2036	PE2018000084	No
Philippines	4	17/07/2036	PH12018500132	Yes, MPP license
Russian Federation	11	17/07/2036	EA201890334	No
Serbia	11	17/10/2037	EP17196993	No
South Africa	13	17/07/2036	ZA201801082	Yes, MPP license
Tajikistan	8	17/07/2036	EA201890334	No
Thailand	2	11/10/2031	TH1301001948	No
Turkey	10	17/10/2037	EP17196993	No
Turkmenistan	8	17/07/2036	EA201890334	Yes, MPP license
Ukraine	2	11/10/2031	UAU201305877	No
United Arab Emirates	2	11/10/2031	GC2011019503	No
Uruguay	3	18/10/2032	UY34401	No
Venezuela	2	10/10/2031	VE2011001332	Yes, MPP license
Viet Nam	5	17/07/2036	VN1201800634	No

Ledipasvir + Sofosbuvir

There are 82 jurisdictions with 564 active filings. The first date of expiration is set for 2024; the latest patent is set to expire in Costa Rica on August 30, 2035.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	15	29/01/2034	EP14704502	No
Argentina	6	30/01/2034	ARP140100352	No
Armenia	13	29/01/2034	EA201490806	Yes, bilateral license
Azerbaijan	13	29/01/2034	EA201490806	No
Bahamas	2	29/01/2034	BS2561	No
Belarus	13	29/01/2034	EA201490806	Yes, bilateral license
Benin	4	30/01/2034	OA1201500300	Yes, bilateral license
Bolivia	2	27/11/2032	BO20120434	Yes, bilateral license
Bosnia and Herzegovina	4	30/03/2031	BAEP11714465	No
Botswana	6	29/01/2034	AP201508630	Yes, bilateral license

Brazil	10	26/11/2032	BR112014012739	No
Burkina Faso	4	30/01/2034	OA1201500300	Yes, bilateral license
Cameroon	4	30/01/2034	OA1201500300	Yes, bilateral license
Central African Republic	4	30/01/2034	OA1201500300	Yes, bilateral license
Chad	4	30/01/2034	OA1201500300	Yes, bilateral license
Chile	7	30/07/2035	CL2015002164	No
China	23	29/01/2034	CN201610111865	No
Colombia	5	29/01/2034	CO15-203.177	No
Comoros	1	30/01/2034	OA1201500300	Yes, bilateral license
Congo	4	30/01/2034	OA1201500300	Yes, bilateral license
Costa Rica	5	30/08/2035	CR20150453	No
Côte d'Ivoire	4	30/01/2034	OA1201500300	Yes, bilateral license
Ecuador	4	29/01/2034	ECIEPI-2015-37311	No
Egypt	6	29/01/2034	EGPCT790/2014	Yes, bilateral license
El Salvador	3	29/01/2034	SVE-5026-2015	Yes, bilateral license
Equatorial Guinea	4	30/01/2034	OA1201500300	Yes, bilateral license
Eswatini (formerly Swaziland)	6	29/01/2034	AP201508630	Yes, bilateral license
Ethiopia	2	11/5/2030	ET20170243	Yes, bilateral license
Gabon	4	30/01/2034	OA1201500300	Yes, bilateral license
Gambia	8	29/01/2034	AP201508630	Yes, bilateral license
Ghana	6	29/01/2034	AP201508630	Yes, bilateral license
Guinea	4	30/01/2034	OA1201500300	Yes, bilateral license
Guinea-Bissau	4	30/01/2034	OA1201500300	Yes, bilateral license
India	8	29/01/2034	IN3953/DELNP/2014	Yes, bilateral license
Indonesia	8	29/01/2034	IDP00201504713	Yes, bilateral license
Kazakhstan	13	29/01/2034	EA201490806	Yes, bilateral license
Kenya	6	29/01/2034	AP201508630	Yes, bilateral license
Kiribati	2	11/5/2030	KI2017016	Yes, bilateral license
Kyrgyz Republic	13	29/01/2034	EA201490806	Yes, bilateral license
Lesotho	6	29/01/2034	AP201508630	Yes, bilateral license
Liberia	6	29/01/2034	AP201508630	Yes, bilateral license

Malawi	6	29/01/2034	AP201508630	Yes, bilateral license
Malaysia	7	30/01/2034	MYPI2015001926	Yes, bilateral license
Mali	4	30/01/2034	OA1201500300	Yes, bilateral license
Mauritania	4	30/01/2034	OA1201500300	Yes, bilateral license
Mexico	17	29/01/2034	MX2014005955	No
Moldova, Republic of	12	29/01/2034	MD20150080	No
Montenegro	9	13/09/2032	MEP201842	No
Mozambique	6	29/01/2034	AP201508630	Yes, bilateral license
Namibia	6	29/01/2034	AP201508630	Yes, bilateral license
Nauru	1	11/5/2030	NR2430014	Yes, bilateral license
Nepal	2	11/5/2030	NP41	Yes, bilateral license
Niger	4	30/01/2034	OA1201500300	Yes, bilateral license
North Macedonia	15	29/01/2034	EP14704502	No
Pakistan	7	30/01/2034	PK0054/2014	Yes, bilateral license
Panama	3	30/07/2035	PA90777	No
Paraguay	2	27/11/2032	PY2012056476	Yes, bilateral license
Peru	6	29/01/2034	PE2015001594	No
Philippines	9	29/01/2034	PH12015501710	Yes, bilateral license
Russian Federation	16	29/01/2034	EA201490806	No
Rwanda	3	29/01/2034	AP201508630	Yes, bilateral license
Senegal	4	30/01/2034	OA1201500300	Yes, bilateral license
Serbia	14	29/01/2034	EP14704502	No
Seychelles	2	11/5/2030	SC2430014	Yes, bilateral license
Sierra Leone	6	29/01/2034	AP201508630	Yes, bilateral license
South Africa	14	30/01/2034	ZA201505718	Yes, bilateral license
Sudan	6	29/01/2034	AP201508630	Yes, bilateral license
Tajikistan	13	29/01/2034	EA201490806	Yes, bilateral license
Tanzania, United Republic of	6	29/01/2034	AP201508630	Yes, bilateral license
Thailand	7	26/11/2032	TH1401002830	Yes, bilateral license
Togo	4	30/01/2034	OA1201500300	Yes, bilateral license
Turkey	24	29/01/2034	EP14704502	No

Turkmenistan	13	29/01/2034	EA201490806	Yes, bilateral license
Tuvalu	1	11/5/2030	TVP2430014	Yes, bilateral license
Uganda	6	29/01/2034	AP201508630	Yes, bilateral license
Ukraine	6	29/01/2034	UAA201508402	Yes, bilateral license
United Arab Emirates	5	29/01/2034	GC201426346	No
Uruguay	8	30/01/2034	UY35299	No
Venezuela	4	30/01/2034	VE92-2014	No
Viet Nam	4	30/01/2034	VN1201502805	Yes, bilateral license
Zambia	6	29/01/2034	AP201508630	Yes, bilateral license
Zimbabwe	6	29/01/2034	AP201508630	Yes, bilateral license

Lenalidomide

There are 51 jurisdictions with 100 active filings. The first date of expiration was 2017; the latest patent is set to expire in the Russian Federation on September 6, 2030. One patent in Brazil, BR0016903, is set to expire October 23, 2020.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	2	1/8/2027	EP07811048	No
Argentina	1	2/10/2026	ARP060104355	No
Armenia	1	2/9/2024	EA200600535	No
Azerbaijan	1	2/9/2024	EA200600535	No
Belarus	1	2/9/2024	EA200600535	No
Benin	1	2/9/2024	OA1200600078	No
Bosnia and Herzegovina	2	1/8/2027	EP07811048	No
Brazil	7	2/10/2026	BRPI0616670	No
Burkina Faso	1	2/9/2024	OA1200600078	No
Cameroon	1	2/9/2024	OA1200600078	No
Central African Republic	1	2/9/2024	OA1200600078	No
Chad	1	2/9/2024	OA1200600078	No
Chile	1	30/07/2027	CL2007002218	No

China	6	1/8/2027	CN200780036550	No
Congo	1	2/9/2024	OA1200600078	No
Costa Rica	4	4/8/2029	CR10967	No
Côte d'Ivoire	1	2/9/2024	OA1200600078	No
Cuba	1	2/9/2024	CU20060055	No
Equatorial Guinea	1	2/9/2024	OA1200600078	No
Gabon	1	2/9/2024	OA1200600078	No
Georgia	1	2/9/2024	GEAP2004009329	No
Guinea	1	2/9/2024	OA1200600078	No
Guinea-Bissau	1	2/9/2024	OA1200600078	No
Indonesia	1	2/9/2024	ID00200600913	No
Kazakhstan	1	2/9/2024	EA200600535	No
Kosovo	1	2/9/2024	KV973	No
Kyrgyz Republic	1	2/9/2024	EA200600535	No
Mali	1	2/9/2024	OA1200600078	No
Mauritania	1	2/9/2024	OA1200600078	No
Mexico	14	1/8/2027	MX2009001268	No
Moldova, Republic of	1	2/9/2024	EA200600535	No
Mongolia	1	2/9/2024	MN3732	No
Montenegro	4	1/8/2027	MEP54110	No
Morocco	1	2/4/2026	MA28911	No
Nicaragua	1	2/9/2024	NI2006000521	No
Niger	1	2/9/2024	OA1200600078	No
North Macedonia	1	1/8/2027	EP07811048	No
Philippines	2	2/9/2024	PH12006500458	No
Russian Federation	4	6/9/2030	RU2010137395	No
Senegal	1	2/9/2024	OA1200600078	No
Serbia	4	1/8/2027	EP07811048	No
South Africa	6	2/10/2026	ZA200803700	No
Sri Lanka	1	2/9/2024	LK14012	No
Tajikistan	1	2/9/2024	EA200600535	No

Togo	1	2/9/2024	OA1200600078	No
Turkey	4	1/8/2027	EP07811048	No
Turkmenistan	1	2/9/2024	EA200600535	No
Ukraine	3	2/10/2026	UAA200805327	No
Uzbekistan	1	2/9/2024	UZIAP20060110	No
Viet Nam	1	2/9/2024	VN1200600527	No
Yugoslavia/Serbia and Montenegro	1	2/9/2024	YUP20060158	No

Lopinavir + Ritonavir

There are 38 jurisdictions with 122 active filings. The first date of expiration was 2012; the latest patent is set to expire in Dominican Republic on July 16, 2039. The majority of remaining patents are set to expire either August 2024 or February 2026. Three patents are set to expire in 2020: UY026324 in Turkey on August 30, 2020, and CN01807688 in China and UY026324 in Uruguay on November 9, 2020.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	3	22/02/2026	AL/P/2011/3804	Commitment to not enforce
Armenia	5	20/02/2026	EA200701790	Commitment to not enforce
Azerbaijan	5	20/02/2026	EA200701790	Commitment to not enforce
Belarus	5	20/02/2026	EA200701790	Commitment to not enforce
Belize	1	20/02/2026	BZ481.07	Commitment to not enforce
Bosnia and Herzegovina	2	20/02/2026	EP18186194	Commitment to not enforce
Brazil	4	20/02/2026	BR122012031169	Commitment to not enforce
Chile	4	20/02/2026	CL200600393	Commitment to not enforce
China	5	20/02/2026	CN200680013668	Commitment to not enforce
Dominican Republic	2	16/07/2039	DO2019000185	Commitment to not enforce
Ecuador	1	22/08/2024	ECSP066397	Commitment to not enforce
El Salvador	1	21/02/2026	SV2006002427	Commitment to not enforce
Georgia	1	20/02/2026	GEAP2006010274	Commitment to not enforce
Guatemala	1	13/09/2029	GT200600295	Commitment to not enforce
Honduras	1	15/02/2026	HN2010001333	Commitment to not enforce

Indonesia	1	22/08/2024	ID200600560	Commitment to not enforce
Kazakhstan	5	20/02/2026	EA200701790	Commitment to not enforce
Kyrgyz Republic	5	20/02/2026	EA200701790	Commitment to not enforce
Malaysia	4	23/05/2027	MYPI0402546	Commitment to not enforce
Mexico	5	4/7/2026	MXPA02009559	Commitment to not enforce
Moldova, Republic of	5	20/02/2026	EA200701790	Commitment to not enforce
Montenegro	2	22/08/2024	MEP17608	Commitment to not enforce
Nicaragua	2	20/02/2026	NI200700219	Commitment to not enforce
Panama	1	21/02/2026	PA8664801	Commitment to not enforce
Peru	2	21/02/2026	PE2009001179	Commitment to not enforce
Philippines	4	20/02/2026	PH12007501802	Commitment to not enforce
Russian Federation	5	20/02/2026	EA200701790	Commitment to not enforce
Serbia	4	20/02/2026	EP18186194	Commitment to not enforce
South Africa	4	20/02/2026	ZA200707022	Commitment to not enforce; MPP license
Sri Lanka	2	20/02/2026	LK14598	Commitment to not enforce
Tajikistan	3	22/08/2024	EA200900292	Commitment to not enforce
Thailand	1	21/02/2026	TH0601000766	Commitment to not enforce
Turkey	13	20/02/2026	EP10159672	Commitment to not enforce
Turkmenistan	5	20/02/2026	EA200701790	Commitment to not enforce
Ukraine	2	20/02/2026	UAA200710440	Commitment to not enforce
Uruguay	3	22/02/2026	UY29391	Commitment to not enforce
Venezuela	1	21/02/2026	VE2006000342	Commitment to not enforce
Viet Nam	2	20/02/2026	VN1200701909	Commitment to not enforce

Meropenem + Vaborbactam

There are 15 jurisdictions with 19 active filings. The first dates of expiration are set for August 2023; the latest patents are set to expire in August 2031.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	2	7/8/2031	EP18183968	No

Brazil	1	7/8/2031	BR112013003045	No
Chile	1	7/8/2031	CL2013000399	No
China	1	7/8/2031	CN201180046975	No
India	1	7/8/2031	IN1146/DELNP/2013	No
Lao People's Democratic Republic	1	7/8/2031	LAPT234	No
Malaysia	1	7/11/2023	MY2013000386	No
Mexico	1	7/8/2031	MX2013001517	No
North Macedonia	2	7/8/2031	EP11816882	No
Russian Federation	1	7/8/2031	RU2013104951	No
Serbia	1	7/8/2031	EP18183968	No
South Africa	1	7/8/2031	ZA201301014	No
Thailand	1	7/8/2023	TH1301000670	No
Turkey	3	7/8/2031	EP11816882	No
Viet Nam	1	7/8/2023	VN1201300725	No

Moxifloxacin

There are four jurisdictions with four total active filings. The first date of expiration was 2009; the latest patent is set to expire in Brazil on October 31, 2021. Malaysia patent MYPI9904825 is set to expire in 2020.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Brazil	1	31/10/2021	BR9915208	No
Cuba	1	9/5/2021	CU20010114	No
Malaysia	1	29/12/2020	MYPI9904825	No
Morocco	1	9/5/2021	MA26189	No

Nilotinib

There are 50 jurisdictions with 164 active filings. The first dates of expiration are set to expire July 2023; the latest patent is set to expire in Tunisia on May 6, 2032.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	7	16/11/2030	EP10781781	No
Algeria	3	16/11/2030	DZ120382	No
Argentina	4	14/11/2030	ARP100104212	No
Barbados	1	17/07/2026	BB200101377	No
Belize	1	17/07/2026	BZ497.07	No
Bolivia	2	19/07/2026	BOSP260180	No
Bosnia and Herzegovina	7	16/11/2030	EP10781781	No
Brazil	6	16/11/2030	BR112012011693	No
Chile	3	25/09/2027	CL2007002766	No
China	5	16/11/2030	CN201080051819	No
Colombia	3	24/09/2027	CO09041795	No
Cuba	2	17/07/2026	CU20080006	No
Ecuador	3	16/11/2030	ECSP12011903	No
Egypt	2	17/07/2026	EG2008000058	No
Georgia	1	17/07/2026	GEAP2006010480	No
Guatemala	3	16/11/2030	GT201200150	No
Honduras	1	17/07/2026	HN2008000311	No
India	2	17/07/2026	IN9925/DELNP/2007	No
Indonesia	3	16/11/2030	ID00201201854	No
Iraq	3	1/11/2030	IQ328/2010	No
Jordan	4	13/11/2030	JO2010396	No
Korea, DPR of	1	17/07/2026	KP07-4692	No
Kosovo	1	17/07/2026	KV20080215	No
Lebanon	3	10/11/2030	LB201009197	No
Libya	1	17/07/2026	LY200803555	No
Malaysia	5	16/11/2030	MYPI2012001993	No
Mexico	5	16/11/2030	MX2012005694	No
Montenegro	2	16/11/2030	MEP8916	No
Morocco	4	16/11/2030	MA34855	No
Nicaragua	1	17/07/2026	NI200800017	No

North Macedonia	7	16/11/2030	EP10781781	No
Pakistan	3	14/11/2030	PK20100967	No
Panama	2	19/07/2026	PA8687301	No
Paraguay	2	19/07/2026	PY2006020442	No
Peru	3	24/09/2027	PE2007001294	No
Philippines	5	16/11/2030	PH12012500965	No
Russian Federation	8	16/11/2030	RU2012124811	No
Serbia	9	16/11/2030	RSP20160303	No
South Africa	5	16/11/2030	ZA201203328	No
Sri Lanka	1	17/07/2026	LK14792	No
Syrian Arab Republic	1	17/07/2026	SY2006007763	No
Thailand	3	16/07/2026	TH0601003348	No
Trinidad and Tobago	1	17/07/2026	TT200700314	No
Tunisia	5	6/5/2032	TNSN20120206	No
Turkey	9	16/11/2030	EP10781781	No
United Arab Emirates	3	9/11/2030	GC2010017112	No
Uruguay	2	19/07/2026	UY29682	No
Uzbekistan	1	17/07/2026	UZ20080049	No
Venezuela	3	15/11/2030	VE2010001791	No
Viet Nam	2	17/07/2026	VN1200800388	No

Nivolumab

There are 26 jurisdictions with 453 active filings. The first date of expiration was 2017; the latest patent is set to expire in Argentina on May 29, 2037.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	11	2037-03-29	110733	Unknown (DPW)
Armenia	22	2036-05-11	201892579	Unknown (DPW)
Azerbaijan	22	2036-05-11	201892579	Unknown (DPW)
Belarus	22	2036-05-11	201892579	Unknown (DPW)

Brazil	29	2036-06-13	112018075660	Unknown (DPW)
Chile	9	2036-01-08	2018001845	Unknown (DPW)
China	76	2036-09-15	110114057	Unknown (DPW)
Colombia	4	2035-10-01	2018004743	Unknown (DPW)
Costa Rica	1	2035-01-28	20170351	Unknown (DPW)
Dominican Republic	1	2035-01-28	P2017000171	Unknown (DPW)
India	1	2031-03-08	137DEN2015	Unknown (DPW)
Kazakhstan	22	2036-05-11	201892579	Unknown (DPW)
Korea, DPR of	51	2036-09-15	20190096936	Unknown (DPW)
Kyrgyz Republic	22	2036-05-11	201892579	Unknown (DPW)
Mexico	37	2036-05-18	2018013509	Unknown (DPW)
Morocco	3	2034-11-05	40290	Unknown (DPW)
Peru	12	2035-09-21	20181093	Unknown (DPW)
Philippines	9	2036-01-08	12018501361	Unknown (DPW)
Russian Federation	38	2035-09-21	2018111459	Unknown (DPW)
Serbia	2	2033-12-24	58014	Unknown (DPW)
South Africa	3	2035-01-28	201704818	Unknown (DPW)
Tajikistan	22	2036-05-11	201892579	Unknown (DPW)
Tunisia	4	2034-11-05	2017000165	Unknown (DPW)
Turkey	1	2037-02-20	201702500	Unknown (DPW)
Turkmenistan	22	2036-05-11	201892579	Unknown (DPW)
Uruguay	7	2035-06-01	36701	Unknown (DPW)

Ombitasvir + Paritaprevir + Ritonavir

There are 23 jurisdictions with 201 active filings. The first date of expiration was 2012; the latest patents are set to expire August 2036.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	10	31/08/2036	EP16766172	No
Argentina	6	9/6/2031	ARP110102023	No

Armenia	10	8/6/2031	EA201291394	No
Azerbaijan	10	2/9/2031	EA201291394	No
Belarus	10	8/6/2031	EA201291394	No
Brazil	6	8/6/2031	BR212012031500	No
Chile	5	6/8/2033	CL2013002299	No
China	10	31/08/2036	CN201680063114	No
Dominican Republic	3	8/6/2031	DO2012000307	No
India	3	8/6/2031	IN11220/DELNP/2012	No
Kazakhstan	10	8/6/2031	EA201291394	No
Kyrgyz Republic	10	8/6/2031	EA201291394	No
Mexico	7	31/08/2036	MX2018002707	No
Nicaragua	1	22/08/2024	NI200600051	No
North Macedonia	15	31/08/2036	EP16766172	No
Philippines	5	8/2/2035	PH12015500289	No
Russian Federation	10	8/6/2031	EA201291394	No
Serbia	11	31/08/2036	EP16766172	No
South Africa	9	8/6/2031	ZA201300112	No
Tajikistan	6	9/6/2030	EA201400115	No
Turkey	21	31/08/2036	EP16766172	No
Turkmenistan	9	9/6/2030	EA201300495	No
Ukraine	7	8/6/2031	UAA201300334	No
Uruguay	7	7/1/2034	UY35259	No

Pegaspargase

There are 34 jurisdictions with 294 active filings. The first date of expiration was 1989; the latest patents are set to expire June 13, 2036.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Argentina	6	2031-05-13	086372	Unknown (DPW)
Armenia	7	2030-03-01	201290843	Unknown (DPW)

Azerbaijan	7	2030-03-01	201290843	Unknown (DPW)
Belarus	7	2030-03-01	201290843	Unknown (DPW)
Brazil	18	2036-06-13	112018075660	Unknown (DPW)
Chile	1	2026-12-05	2007003508	Unknown (DPW)
China	59	2036-06-13	109562086	Unknown (DPW)
Colombia	6	2031-08-04	6870039	Unknown (DPW)
Costa Rica	3	2031-08-04	20140063	Unknown (DPW)
Cuba	3	2031-08-04	20140012	Unknown (DPW)
Dominican Republic	3	2031-08-04	P2014000022	Unknown (DPW)
Ecuador	3	2031-08-04	SP14013192	Unknown (DPW)
El Salvador	1	2026-12-05	2009003288	Unknown (DPW)
Guatemala	2	2026-12-05	200900154	Unknown (DPW)
Honduras	2	2026-12-05	2009001131	Unknown (DPW)
India	1	2029-07-02	248DEN2012	Unknown (DPW)
Jordan	1	2026-12-05	3147	Unknown (DPW)
Kazakhstan	7	2030-03-01	201290843	Unknown (DPW)
Korea, DPR of	41	2036-06-13	20190017913	Unknown (DPW)
Kyrgyz Republic	7	2030-03-01	201290843	Unknown (DPW)
Malaysia	5	2029-01-12	160399	Unknown (DPW)
Mexico	23	2031-08-04	2014001393	Unknown (DPW)
Morocco	2	2026-12-05	31283	Unknown (DPW)
Panama	1	2026-12-05	8759601	Unknown (DPW)
Peru	3	2026-12-05	14442008	Unknown (DPW)
Russian Federation	34	2030-03-01	201290843	Unknown (DPW)
Serbia	3	2028-05-13	54428	Unknown (DPW)
South Africa	15	2029-11-16	201204356	Unknown (DPW)
Tajikistan	7	2030-03-01	201290843	Unknown (DPW)
Tunisia	3	2031-08-04	2014000046	Unknown (DPW)
Turkey	3	2029-01-29	201910822	Unknown (DPW)
Turkmenistan	7	2030-03-01	201290843	Unknown (DPW)
Ukraine	1	2026-12-05	96965	Unknown (DPW)

Uruguay	2	2026-12-05	30761	Unknown (DPW)
---------	---	------------	-------	---------------

Plazomicin

There are 14 jurisdictions with 16 active filings. 15 patents are set to expire November 20, 2028; the one remaining patent is set to expire in Brazil on January 14, 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Armenia	1	20/11/2028	EA201070597	No
Azerbaijan	1	20/11/2028	EA201070597	No
Belarus	1	20/11/2028	EA201070597	No
Brazil	1	14/01/2029	BRPI0819319	No
China	2	20/11/2028	CN201310142186	No
India	1	20/11/2028	IN4165/DELNP/2010	No
Kazakhstan	1	20/11/2028	EA201070597	No
Kyrgyz Republic	1	20/11/2028	EA201070597	No
Mexico	1	20/11/2028	MX2010005632	No
Moldova, Republic of	1	20/11/2028	EA201070597	No
Russian Federation	1	20/11/2028	EA201070597	No
Tajikistan	1	20/11/2028	EA201070597	No
Turkey	2	20/11/2028	EP16195678	No
Turkmenistan	1	20/11/2028	EA201070597	No

Raltegravir

There are 47 jurisdictions with 84 active filings. The first dates of expiration are set for October 2022; the latest patents are set to expire October 20, 2030.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	3	20/10/2030	EP10827338	No
Algeria	2	1/12/2025	DZ070325	No
Argentina	1	1/12/2025	ARP140101707	No

Barbados	1	1/12/2025	BB200101317	No
Belarus	2	1/12/2025	EA200701204	No
Belize	1	1/12/2025	BZ20070468	No
Bosnia and Herzegovina	1	1/12/2025	BAE00794	No
Brazil	4	20/10/2030	BR112012009857	No
Chile	2	1/12/2025	CL200503144	No
China	5	20/10/2030	CN201610500807	No
Colombia	2	1/12/2025	CO07055540	No
Ecuador	1	20/10/2022	ECSP045074	No
Egypt	1	1/12/2025	EG2007000534	No
Gambia	1	20/10/2022	GM1441735	No
Georgia	2	1/12/2025	GEAP2005010157	No
India	3	20/10/2030	IN3377DEN2012	No
Indonesia	2	1/12/2025	ID200701697	No
Kazakhstan	2	1/12/2025	EA200701204	No
Kiribati	1	20/10/2022	KI144735	No
Lebanon	1	29/11/2025	LB05007367	No
Malaysia	2	20/10/2030	MYPI2012001823	No
Mexico	4	20/10/2030	MX2012004903	No
Mongolia	1	1/12/2027	MN3980	No
Montenegro	2	1/12/2025	MEP2112	No
Morocco	1	1/12/2025	MA30041	No
Nicaragua	1	1/12/2025	NI200700138	No
North Macedonia	1	20/10/2030	EP10827338	No
Pakistan	1	30/11/2025	PK200501139	No
Philippines	2	1/12/2025	PH12007501118	No
Russian Federation	3	20/10/2030	RU2012121857	No
Serbia	2	20/10/2030	EP10827338	No
Seychelles	1	20/10/2022	SC1441735	No
Sierra Leone	1	20/10/2022	SL021606	No
Solomon Islands	1	29/06/2026	SB37/213	No

South Africa	4	20/10/2030	ZA201203012	No
Thailand	2	20/10/2030	TH1201001892	No
Trinidad and Tobago	1	1/12/2025	TT200700120	No
Tunisia	1	31/05/2027	TNSN07215	No
Turkey	5	20/10/2030	EP10827338	No
Tuvalu	1	20/10/2022	TVP1441735	No
Ukraine	2	1/12/2025	UAA200707372	No
United Arab Emirates	1	29/11/2025	GC5453	No
Uzbekistan	1	20/10/2022	UZ20040189	No
Vanuatu	1	20/10/2022	VU22043	No
Venezuela	1	29/11/2025	VE2005002432	No
Viet Nam	2	1/12/2025	VN1200701323	No
Yugoslavia/Serbia and Montenegro	1	20/10/2022	YUP35604	No

Ritonavir

There are 28 jurisdictions with 72 active filings. The first date of expiration was 2012; the latest patent is set to expire in Chile on May 23, 2027. 65 of the 72 patents are all set to expire on August 22, 2024. Two patents are set to expire November 9, 2020: MXPA02004739 in Mexico and EP00977140 in Turkey. The five remaining patents are: CL199901611 in Chile set to expire May 23, 2027; MYPI9903007 and MYPI0402546 in Malaysia set to expire February 27, 2021, and January 12, 2027, respectively; PH11993047529 in Philippines set to expire March 14, 2021; and EP01957809 in Turkey set to expire May 28, 2021.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	2	22/08/2024	AL/P/2011/3804	Commitment to not enforce
Armenia	4	22/08/2024	EA200600473	Commitment to not enforce
Azerbaijan	4	22/08/2024	EA200600473	Commitment to not enforce
Belarus	4	22/08/2024	EA200600473	Commitment to not enforce
Bosnia and Herzegovina	1	22/08/2024	BAP062383	Commitment to not enforce
Brazil	2	22/08/2024	BR122012002862	Commitment to not enforce
Chile	1	23/05/2027	CL199901611	Commitment to not enforce
China	3	22/08/2024	CN201010222734	Commitment to not enforce

Ecuador	1	22/08/2024	ECSP066397	Commitment to not enforce
Indonesia	1	22/08/2024	ID200600560	Commitment to not enforce
Kazakhstan	4	22/08/2024	EA200600473	Commitment to not enforce
Kyrgyz Republic	4	22/08/2024	EA200600473	Commitment to not enforce
Malaysia	2	12/1/2027	MYPI0402546	Commitment to not enforce
Mexico	3	22/08/2024	MX2010013145	Commitment to not enforce
Moldova, Republic of	4	22/08/2024	EA200600473	Commitment to not enforce
Montenegro	2	22/08/2024	MEP17608	Commitment to not enforce
Nicaragua	1	22/08/2024	NI200600051	Commitment to not enforce
North Macedonia	2	22/08/2024	EP17210362	Commitment to not enforce
Philippines	1	14/03/2021	PH11993047529	Commitment to not enforce
Russian Federation	4	22/08/2024	EA200600473	Commitment to not enforce
Serbia	1	22/08/2024	RSP20181262	Commitment to not enforce
South Africa	3	22/08/2024	ZA200601718	Commitment to not enforce; MPP license
Sri Lanka	1	22/08/2024	LK13996	Commitment to not enforce
Tajikistan	3	22/08/2024	EA200900292	Commitment to not enforce
Turkey	8	22/08/2024	EP04816820	Commitment to not enforce
Turkmenistan	4	22/08/2024	EA200600473	Commitment to not enforce
Ukraine	1	22/08/2024	UAA200603276	Commitment to not enforce
Viet Nam	1	22/08/2024	VN1200600476	Commitment to not enforce

Rituximab

There are 14 jurisdictions with 26 active filings. The first date of expiration was 2004; the latest patent is set to expire in Malaysia on December 14, 2030. Eight patents covering six jurisdictions are set to expire in 2020: EP15160406 in Albania on August 1, 2020; BR0011197 in Brazil on May 3, 2020; CN00809834 and CN200710185086 in China on May 3, 2020; MXPA02001333 and MXPA01011279 in Mexico on August 1, 2020, and May 3, 2020, respectively; EP15160406 in North Macedonia on August 1, 2020; and ZA200108673 in South Africa on May 3, 2020.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	2	13/11/2026	EP06837634	No

Bosnia and Herzegovina	1	13/11/2026	EP06837634	No
Brazil	1	3/5/2020	BR0011197	No
China	3	13/11/2026	CN200680050934	No
Malaysia	5	14/12/2030	MYP19904860	No
Mexico	3	13/11/2026	MX2008006113	No
Morocco	1	13/11/2026	MA31025	No
North Macedonia	2	13/11/2026	EP06837634	No
Philippines	1	21/07/2022	PH11990347257	No
Russian Federation	1	13/11/2026	RU2008123794	No
Serbia	2	13/11/2026	RSP20150031	No
South Africa	2	13/11/2026	ZA200804288	No
Turkey	1	13/11/2026	EP06837634	No
Ukraine	1	13/11/2026	UAA200808025	No

Sofosbuvir

There are 78 jurisdictions with 338 active filings. The first date of expiration is 2024; the latest patent is set to expire in the Russian Federation on January 29, 2038.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	10	26/11/2032	EP12795307	No
Argentina	5	19/12/2037	ARP170103608	No
Armenia	7	26/11/2032	EA201490903	Yes, bilateral license
Azerbaijan	7	26/11/2032	EA201490903	No
Belarus	7	26/11/2032	EA201490903	Yes, bilateral license
Benin	2	26/11/2032	OA1201400229	Yes, bilateral license
Bolivia	1	27/11/2032	BO20120434	Yes, bilateral license
Bosnia and Herzegovina	3	30/03/2031	BAEP11714465	No
Botswana	3	26/11/2032	AP201407699	Yes, bilateral license
Brazil	7	26/11/2032	BR112014012739	No
Burkina Faso	2	26/11/2032	OA1201400229	Yes, bilateral license

Cameroon	2	26/11/2032	OA1201400229	Yes, bilateral license
Central African Republic	2	26/11/2032	OA1201400229	Yes, bilateral license
Chad	2	26/11/2032	OA1201400229	Yes, bilateral license
Chile	6	26/11/2032	CL2014001397	No
China	14	26/11/2032	CN201280058114	No
Colombia	3	13/09/2032	CO14078217	No
Congo	2	26/11/2032	OA1201400229	Yes, bilateral license
Costa Rica	4	26/11/2032	CR20140273	No
Côte d'Ivoire	2	26/11/2032	OA1201400229	Yes, bilateral license
Ecuador	2	26/11/2032	ECSP14005678	No
Egypt	5	26/11/2032	EG2014000864	Yes, bilateral license
El Salvador	2	26/11/2032	SV2014004722	Yes, bilateral license
Equatorial Guinea	2	26/11/2032	OA1201400229	Yes, bilateral license
Eswatini (formerly Swaziland)	3	26/11/2032	AP201407699	Yes, bilateral license
Ethiopia	1	25/03/2028	ET20170238	Yes, bilateral license
Gabon	2	26/11/2032	OA1201400229	Yes, bilateral license
Gambia	4	26/11/2032	AP201407699	Yes, bilateral license
Ghana	3	26/11/2032	AP201407699	Yes, bilateral license
Guinea	2	26/11/2032	OA1201400229	Yes, bilateral license
Guinea-Bissau	2	26/11/2032	OA1201400229	Yes, bilateral license
India	6	26/11/2032	IN4542/DELNP/2014	Yes, bilateral license
Indonesia	6	26/11/2032	ID00201403478	Yes, bilateral license
Kazakhstan	7	26/11/2032	EA201490903	Yes, bilateral license
Kenya	3	26/11/2032	AP201407699	Yes, bilateral license
Kiribati	1	25/03/2028	KI2017014	Yes, bilateral license
Kyrgyz Republic	7	26/11/2032	EA201490903	Yes, bilateral license
Lesotho	3	26/11/2032	AP201407699	Yes, bilateral license
Liberia	3	26/11/2032	AP201407699	Yes, bilateral license
Malawi	3	26/11/2032	AP201407699	Yes, bilateral license
Malaysia	6	26/11/2032	MYPI2014001520	Yes, bilateral license
Mali	2	26/11/2032	OA1201400229	Yes, bilateral license

Mauritania	2	26/11/2032	OA1201400229	Yes, bilateral license
Mexico	10	26/11/2032	MX2014006373	No
Moldova, Republic of	7	26/11/2032	MD20140058	No
Montenegro	5	13/09/2032	MEP201842	No
Mozambique	3	26/11/2032	AP201407699	Yes, bilateral license
Namibia	3	26/11/2032	AP201407699	Yes, bilateral license
Nepal	1	25/03/2028	NP14	Yes, bilateral license
Niger	2	26/11/2032	OA1201400229	Yes, bilateral license
North Macedonia	10	26/11/2032	EP12795307	No
Pakistan	4	27/11/2032	PK20120803	Yes, bilateral license
Panama	2	13/09/2032	PA9014101	No
Paraguay	1	27/11/2032	PY2012056476	Yes, bilateral license
Peru	3	26/11/2032	PE2014000749	No
Philippines	8	26/11/2032	PH12014501133	Yes, bilateral license
Russian Federation	10	29/01/2038	RU2018103329	No
Rwanda	2	26/11/2032	AP201407699	Yes, bilateral license
Senegal	2	26/11/2032	OA1201400229	Yes, bilateral license
Serbia	9	26/11/2032	EP12795307	No
Seychelles	1	25/03/2028	SC2203462	Yes, bilateral license
Sierra Leone	3	26/11/2032	AP201407699	Yes, bilateral license
South Africa	10	26/11/2032	ZA201404061	Yes, bilateral license
Sudan	3	26/11/2032	AP201407699	Yes, bilateral license
Tajikistan	7	26/11/2032	EA201490903	Yes, bilateral license
Tanzania, United Republic of	3	26/11/2032	AP201407699	Yes, bilateral license
Thailand	6	26/11/2032	TH1401002830	Yes, bilateral license
Togo	2	26/11/2032	OA1201400229	Yes, bilateral license
Turkey	19	26/11/2032	EP12795307	No
Turkmenistan	7	26/11/2032	EA201490903	Yes, bilateral license
Uganda	3	26/11/2032	AP201407699	Yes, bilateral license
Ukraine	4	26/11/2032	UAA201405757	Yes, bilateral license
United Arab Emirates	4	27/11/2032	GCP2012022917	No

Uruguay	5	27/11/2032	UY34474	No
Venezuela	3	27/11/2032	VE2012001526	No
Viet Nam	2	26/11/2032	VN1201401861	Yes, bilateral license
Zambia	3	26/11/2032	AP201407699	Yes, bilateral license
Zimbabwe	3	26/11/2032	AP201407699	Yes, bilateral license

Sofosbuvir + Velpatasvir

There are 87 jurisdictions with 502 active filings. The first date of expiration is 2024; the latest patents are set to expire January 2034.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	16	29/01/2034	EP14704501	No
Argentina	7	30/01/2034	ARP140100355	No
Armenia	12	29/01/2034	EA201690473	Yes, bilateral license
Azerbaijan	12	29/01/2034	EA201690473	No
Bahamas	1	27/11/2032	BS2462	No
Belarus	12	29/01/2034	EA201690473	Yes, bilateral license
Benin	3	26/11/2032	OA1201400229	Yes, bilateral license
Bolivia	2	27/11/2032	BO20120434	Yes, bilateral license
Bosnia and Herzegovina	6	29/01/2034	EP14704501	No
Botswana	4	26/11/2032	AP201407699	Yes, bilateral license
Brazil	8	26/11/2032	BR112014012739	No
Burkina Faso	3	26/11/2032	OA1201400229	Yes, bilateral license
Cameroon	3	26/11/2032	OA1201400229	Yes, bilateral license
Central African Republic	3	26/11/2032	OA1201400229	Yes, bilateral license
Chad	3	26/11/2032	OA1201400229	Yes, bilateral license
Chile	7	16/05/2033	CL2013001428	No
China	17	29/01/2034	CN201480047195	No
Colombia	4	15/11/2032	CO13122291	No
Congo	3	26/11/2032	OA1201400229	Yes, bilateral license

Costa Rica	5	16/05/2033	CR20130231	No
Côte d'Ivoire	3	26/11/2032	OA1201400229	Yes, bilateral license
Ecuador	3	26/11/2032	ECSP14005678	No
Egypt	6	26/11/2032	EG2014000864	Yes, bilateral license
El Salvador	4	26/11/2032	SV2014004722	Yes, bilateral license
Equatorial Guinea	3	26/11/2032	OA1201400229	Yes, bilateral license
Eswatini (formerly Swaziland)	4	26/11/2032	AP201407699	Yes, bilateral license
Ethiopia	2	15/11/2032	ET20170244	Yes, bilateral license
Fiji	1	25/03/2028	FJ1237	Yes, bilateral license
Gabon	3	26/11/2032	OA1201400229	Yes, bilateral license
Gambia	6	26/11/2032	AP201407699	Yes, bilateral license
Ghana	4	26/11/2032	AP201407699	Yes, bilateral license
Grenada	1	15/11/2032	GD201709	No
Guinea	3	26/11/2032	OA1201400229	Yes, bilateral license
Guinea-Bissau	3	26/11/2032	OA1201400229	Yes, bilateral license
Guyana	2	15/11/2032	GY1676	Yes, bilateral license
India	7	26/11/2032	IN4542/DELNP/2014	Yes, bilateral license
Indonesia	7	26/11/2032	ID00201403478	Yes, bilateral license
Kazakhstan	12	29/01/2034	EA201690473	Yes, bilateral license
Kenya	4	26/11/2032	AP201407699	Yes, bilateral license
Kiribati	2	15/11/2032	KI2017015	Yes, bilateral license
Kyrgyz Republic	12	29/01/2034	EA201690473	Yes, bilateral license
Lesotho	4	26/11/2032	AP201407699	Yes, bilateral license
Liberia	4	26/11/2032	AP201407699	Yes, bilateral license
Malawi	4	26/11/2032	AP201407699	Yes, bilateral license
Malaysia	7	26/11/2032	MYPI2014001520	Yes, bilateral license
Mali	3	26/11/2032	OA1201400229	Yes, bilateral license
Mauritania	3	26/11/2032	OA1201400229	Yes, bilateral license
Mexico	14	29/01/2034	MX2016002185	No
Moldova, Republic of	9	26/11/2032	MD20140058	No
Montenegro	9	29/01/2034	EP14704501	No

Morocco	2	9/6/2033	MA36000	Yes, bilateral license
Mozambique	4	26/11/2032	AP201407699	Yes, bilateral license
Namibia	4	26/11/2032	AP201407699	Yes, bilateral license
Nauru	1	15/11/2032	NR2635588	Yes, bilateral license
Nepal	2	15/11/2032	NP40	Yes, bilateral license
Niger	3	26/11/2032	OA1201400229	Yes, bilateral license
North Macedonia	16	29/01/2034	EP14704501	No
Pakistan	6	27/11/2032	PK20120803	Yes, bilateral license
Panama	3	15/11/2032	PA90000-01	No
Paraguay	2	27/11/2032	PY2012056476	Yes, bilateral license
Peru	5	26/11/2032	PE2014000749	No
Philippines	10	26/11/2032	PH12014501133	Yes, bilateral license
Russian Federation	15	29/01/2034	EA201690473	No
Rwanda	3	26/11/2032	AP201407699	Yes, bilateral license
Saint Lucia	1	25/03/2028	LC201610	No
Senegal	3	26/11/2032	OA1201400229	Yes, bilateral license
Serbia	16	29/01/2034	EP14704501	No
Seychelles	2	15/11/2032	SC2635588	Yes, bilateral license
Sierra Leone	4	26/11/2032	AP201407699	Yes, bilateral license
Solomon Islands	1	25/03/2028	SB37/384	Yes, bilateral license
South Africa	14	26/11/2032	ZA201404061	Yes, bilateral license
Sudan	4	26/11/2032	AP201407699	Yes, bilateral license
Tajikistan	12	29/01/2034	EA201690473	Yes, bilateral license
Tanzania, United Republic of	4	26/11/2032	AP201407699	Yes, bilateral license
Thailand	7	26/11/2032	TH1401002830	Yes, bilateral license
Togo	3	26/11/2032	OA1201400229	Yes, bilateral license
Turkey	25	29/01/2034	EP14704501	No
Turkmenistan	12	29/01/2034	EA201690473	Yes, bilateral license
Tuvalu	1	15/11/2032	TVP200	Yes, bilateral license
Uganda	4	26/11/2032	AP201407699	Yes, bilateral license
Ukraine	6	26/11/2032	UAA201405757	Yes, bilateral license

United Arab Emirates	5	27/11/2032	GCP2012022917	No
Uruguay	8	30/01/2034	UY35300	No
Venezuela	3	27/11/2032	VE2012001526	No
Viet Nam	3	26/11/2032	VN1201401861	Yes, bilateral license
Zambia	4	26/11/2032	AP201407699	Yes, bilateral license
Zimbabwe	4	26/11/2032	AP201407699	Yes, bilateral license

Telmisartan + Hydrochlorothiazide

There are 20 jurisdictions with 30 active filings. The first date of expiration was 2011; the latest patent is set to expire in Chile on November 27, 2023.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Belarus	2	15/01/2022	EA200400879	No
Brazil	3	15/01/2022	BR122013003842-6	No
Chile	1	27/11/2023	CL200000034	No
China	1	15/01/2022	CN02827182	No
Colombia	1	15/01/2022	CO04068737	No
Ecuador	1	15/01/2022	ECSP20045195 Div	No
Indonesia	2	15/01/2022	ID00200803393	No
Kosovo	1	15/01/2022	KV243	No
Mexico	2	15/01/2022	MXPA08012530	No
Montenegro	1	15/01/2022	MEP42408	No
North Macedonia	3	15/01/2022	EP10179142	No
Philippines	1	15/01/2022	PH12004501074	No
Russian Federation	2	15/01/2022	EA200601917	No
South Africa	1	15/01/2022	ZA200405240	No
Turkey	3	15/01/2022	EP07115060	No
Ukraine	1	15/01/2022	UA20040806794	No
United Arab Emirates	1	15/01/2022	AE251-2004	No
Uzbekistan	1	15/01/2022	UZ20040316	No

Viet Nam	1	15/01/2022	VN1200400745	No
Yugoslavia/Serbia and Montenegro	1	15/01/2022	YUP61104	No

Thalidomide

There are five jurisdictions with 10 total active filings. The first date of expiration is 2020; the latest patents are set to expire on November 14, 2022. Three patents are set to expire October 23, 2020: 0016903 in Brazil, 1425167 in China, and PA02006176 in Mexico.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Brazil	2	2022-11-14	0316240	Unknown (DPW)
China	3	2022-11-14	101816626	Unknown (DPW)
Mexico	2	2022-11-14	PA05005162	Unknown (DPW)
South Africa	1	2022-11-14	200503927	Unknown (DPW)
Korea, DPR	2	2022-11-14	100671366	Unknown (DPW)

Tiotropium

There are 58 jurisdictions with 209 active filings. The first date of expiration was 2010; the latest patents are set to expire on March 10, 2029.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	15	10/3/2029	EP09719496	No
Algeria	2	27/09/2021	DZ013477	No
Argentina	2	3/8/2026	ARP060103410	No
Armenia	3	8/10/2021	EA200300429	No
Azerbaijan	3	8/10/2021	EA200300429	No
Belarus	7	1/4/2023	EA200401304	No
Benin	2	27/09/2021	OA1200300107	No
Bosnia and Herzegovina	4	10/3/2029	EP09719496	No
Brazil	8	1/8/2026	BRPI0614394	No
Burkina Faso	2	27/09/2021	OA1200300107	No

Cameroon	2	27/09/2021	OA1200300107	No
Central African Republic	2	27/09/2021	OA1200300107	No
Chad	2	27/09/2021	OA1200300107	No
Chile	5	30/12/2023	CL200102449	No
China	6	1/4/2023	CN03808025	No
Colombia	2	7/10/2024	CO04100971	No
Congo	2	27/09/2021	OA1200300107	No
Costa Rica	2	25/03/2023	CR6937	No
Côte d'Ivoire	2	27/09/2021	OA1200300107	No
Cuba	1	10/4/2023	CU20030082	No
Egypt	4	8/4/2023	EG2003000332	No
Equatorial Guinea	2	27/09/2021	OA1200300107	No
Eswatini (formerly Swaziland)	2	27/09/2021	AP200302774	No
Gabon	2	27/09/2021	OA1200300107	No
Gambia	2	27/09/2021	AP200302774	No
Georgia	2	27/09/2021	GEAP2001005214	No
Ghana	2	27/09/2021	AP200302774	No
Guinea	2	27/09/2021	OA1200300107	No
Guinea-Bissau	2	27/09/2021	OA1200300107	No
Indonesia	5	1/4/2023	IDW00200402207	No
Kazakhstan	3	8/10/2021	EA200300429	No
Kenya	2	27/09/2021	AP200302774	No
Korea, DPR of	1	27/02/2021	KP03-1482	No
Kosovo	1	1/4/2023	KV222	No
Kyrgyz Republic	3	8/10/2021	EA200300429	No
Lesotho	2	27/09/2021	AP200302774	No
Liberia	1	27/09/2021	LR2003-00003	No
Madagascar	1	27/09/2021	MG2003-007	No
Malawi	2	27/09/2021	AP200302774	No
Malaysia	6	8/4/2023	MYPI20031314	No
Mali	2	27/09/2021	OA1200300107	No

Mauritania	2	27/09/2021	OA1200300107	No
Mexico	9	1/8/2026	MX2008001506	No
Moldova, Republic of	3	8/10/2021	EA200300429	No
Mongolia	1	27/09/2021	MN3108	No
Montenegro	8	1/4/2023	MEP47108	No
Morocco	3	7/4/2023	MA27103	No
Mozambique	2	27/09/2021	AP200302774	No
Niger	2	27/09/2021	OA1200300107	No
North Macedonia	15	10/3/2029	EP09719496	No
Pakistan	5	7/4/2023	PK301/2003	No
Peru	3	9/10/2021	PE2001001000	No
Philippines	8	1/8/2026	PH12008500316	No
Russian Federation	8	1/8/2026	RU2008108302	No
Senegal	2	27/09/2021	OA1200300107	No
Serbia	5	10/3/2029	EP09719496	No
Sierra Leone	2	27/09/2021	AP200302774	No
South Africa	8	1/8/2026	ZA200800186	No

Trastuzumab

There are 17 jurisdictions with 55 active filings. The first date of expiration was 2012; the latest patent is set to expire in Brazil on September 24, 2028.

Country	Number of Active Filings	Date of Last Expiration	Patent Number	Subject to Licensing Agreement
Albania	5	20/02/2026	EP16198600	No
Argentina	3	20/04/2026	ARP170101287	No
Bosnia and Herzegovina	1	20/02/2026	EP16198600	No
Brazil	8	24/09/2028	BR0012196	No
Chile	1	20/02/2026	CL2015000428	No
China	8	20/02/2026	CN200680013738	No
Costa Rica	1	20/02/2026	CR9312	No

Guatemala	1	22/02/2026	GT200600092	No
Malaysia	1	20/02/2026	MYPI20060738	No
Mexico	6	20/04/2026	MX2013009514	No
Morocco	1	20/02/2026	MA30217	No
North Macedonia	5	20/02/2026	EP16198600	No
Russian Federation	3	20/02/2026	RU2007135185	No
Serbia	2	20/02/2026	EP16198600	No
South Africa	5	20/02/2026	ZA200707078	No
Turkey	3	20/02/2026	EP16198600	No
Ukraine	1	20/02/2026	UAA200710403	No